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Abstract 
 
Due to the safety concerns surrounding viral vectors, non-viral alternatives 
are desirable for fulfilling the aim of gene therapy. In this project gel mobility 
shift assays demonstrated how cross-linked PVA nanoparticles successfully 
form complexes with plasmid DNA and are of a size and charge that 
should, theoretically, permit endocytosis by eukaryotic cells. However, 
during in vitro transfection studies no reporter (GFP) gene expression was 
noted. The collective evidence from electroporation, fluorescent-DNA-
tagging, Lipofectin® or calcium phosphate chimeric and chloroquine 
experiments suggest that a lack of cell uptake is responsible. Nevertheless, 
the same cross-linked PVA nanoparticles have been shown to exhibit much 
promise in the field of drug delivery during in vitro experiments, even when 
used to target the same cell types as those used during transfection 
studies. Nanagel®, a cross-linked PVA nanoparticle containing budesonide, 
achieved higher levels of drug delivery than a commercially available form 
of the same drug (Pulmicort®) after 1 or 24 hours drug exposure. 
Furthermore, by measuring superoxide production during a stimulated 
respiratory burst, the budesonide delivered to cells appears fully functional 
and significantly more effective than Pulmicort® in preventing the formation 
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of reactive oxygen species, following a 24-hour pre-treatment period with 
the formulation. These findings have exciting possibilities for the use of 
hard-to-dissolve corticosteroids in the treatment of respiratory disease.  
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1. Evaluating the use of cross-linked PVA 
nanoparticles for gene delivery 
 
1.1 Introduction 
 
 
The aim of this project was to investigate whether cross-linked PVA hydrogels 
were able to successfully transfect eukaryotic cells. It was postulated that, 
owing to their positive charge, cross-linked PVA nanoparticles would form 
complexes with DNA through charge interaction and that a net positive 
charge on hydrogel/DNA complexes could facilitate cell uptake. During the 
project PVA-based nanoparticle transfection was compared against 
established transfection technologies in an attempt to validate the hypothesis 
being tested. 
 
Transfection can be simply defined as the transfer of foreign DNA into cells 
and can be either transient or stable. During transient transfection exogenous 
DNA is not integrated into the host cell genome but is instead maintained 
extra-chromosomally within the nucleus. In contrast, during stable 
transfection, exogenous DNA becomes integrated into the host cell genome 
(Reese, 2004).  
 
If naked DNA is applied to cells, however, DNA uptake in those cells is poor 
as naked DNA is unable to penetrate the plasma membrane of most cells 
(Feng et al. 2006). The size and charge of the DNA also prevents efficient 
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uptake (Felgner et al. 1987). As a consequence, carriers or vectors are 
required to deliver exogenous DNA into target cells (Feng et al. 2006). 
 
Workers have developed various means of breaching the plasma membrane 
to deliver DNA into cells, with the ultimate goal of „gene therapy‟ in mind. 
Gene therapy has been described as “the introduction of healthy copies of 
mutated or absent genes into target cells so as to promote the expression of 
a normal protein and to restore correct cellular function” (Mehier-Humbert & 
Guy, 2005). However, despite the fact that gene therapy concepts are well 
established, with the first approved protocol of human gene therapy dating 
back to 1989 (Journal of Gene Medicine, 2007), Gendicine, approved for use 
in China by the Chinese State Food and Drug Administration in 2003 for the 
treatment of head and neck squamous cell carcinoma, remains the only gene 
therapy treatment that has been approved for clinical use (Biopharm 
International, 2004). Although statistics from the Journal of Gene Medicine 
show in excess of 1,000 gene therapy clinical trials have been approved 
worldwide between 1989 and 2007 (Journal of Gene Medicine, 2007), there 
are, at present, no gene therapy treatments clinically available in the USA or 
Europe.  
 
The failure of gene therapy treatments to reach the clinic is a consequence of 
the many problems encountered in both the lab and during clinical trials. 
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1.1.1 Viral Vectors 
 
Genetically modified viruses were the vectors of choice for much of the early 
gene therapy research due to their inherent ability to efficiently transfect cells, 
delivering their DNA to the nucleus to subsequently direct gene expression 
(Maitra, 2005). Viruses have been genetically engineered by deleting genes 
permitting replication, assembly or infection and replacing them with 
therapeutic genes of interest (Gardlik et al., 2005). Recent statistics from the 
Journal of Gene Medicine show that adenoviruses and retroviruses are the 
most popular vectors used during gene therapy research – amounting to 
approximately 45 % of vectors used in clinical trials - whilst poxvirus, vaccinia 
virus, adeno-associated virus and herpes simplex virus have also been used 
to a lesser extent (Journal of Gene Medicine, 2007). 
 
Workers have persisted with the development of viral vectors because, 
broadly speaking, they introduce their DNA into cells with high efficiency 
(Gardlik et al., 2005). However, their clinical use is limited because of 
immunogenicity, cytotoxicity, restricted targeting of specific cell types, limited 
DNA carrying capacity, production and packaging problems and high cost 
(Maitra, 2005). Furthermore, there is always the underlying fear that, through 
recombination, viruses may retrieve genes for assembly and replication that 
were originally removed, rendering them virulent once more (Gardlik et al. 
2005). The cytotoxic and immunogenic responses elicited in patients during 
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clinical trials have even led to the death of several patients and for the US 
Food and Drug Administration to temporarily halt gene therapy trials using 
viral vectors in the past (Weiss, 2005). 
1.1.2 Non-viral vectors 
 
In view of the limitations of utilizing a viral approach for gene delivery, the field 
of gene therapy has moved towards developing non-viral transfection 
techniques which are considered much safer alternatives (Gardlik et al. 
2005). Non-viral vectors have a virtually unlimited capacity for transgenes, 
demonstrate low toxicity allowing repeated application and are much simpler 
to construct (Gardlik et al. 2005). Non-viral approaches developed to date 
include both physical and chemical transfection methods 
1.1.2.1 Physical Methods 
 
The benefit of using physical methods for gene delivery is that transfection 
efficiency is only weakly dependent upon or even independent upon cell type 
– as direct transfer across the plasma membrane is possible (Mehier-
Humbert & Guy, 2005). This means gene transfer to a wide range of cell 
types is thus possible. 
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Electroporation 
 
A well established physical method of efficiently transfecting a wide variety of 
cell types in vitro is electroporation, or electropermeabilisation, a technique 
first used in 1982 by Wong and Neuman to introduce the thymidine kinase (tk) 
gene into tk deficient mouse cells (Wong & Neuman, 1982). Electroporation 
uses brief, high intensity electrical field pulses generated by an electroporator 
to disrupt the lipid matrix in the cell membrane to create tiny pores through 
which DNA can enter the cell from surrounding medium (Harrison et al., 
1998). However, problems associated with this technique are that DNA 
internalized via electroporation is not delivered directly to the nucleus it is still 
subjected to DNase degradation in the cytoplasm (Mehier-Humbert & Guy, 
2005). An additional problem is that during the electroporation procedure the 
electrical currents to which cells are subjected can damage protein channels, 
which in some cases are permanently denatured (Tsong, 1991). 
 
Particle Bombardment 
 
Another physical means of attaining mammalian transfection is to use particle 
bombardment, a modified biolistics technique originally developed as a 
means of transfecting plant cells (Heiser, 1994). The basis of the technique is 
to transport naked DNA into target cells on an accelerated particle carrier 
(Mehier-Humbert & Guy, 2005). Heiser (1994) has used DNA-coated gold 
microparticles, fired though a gas cylinder at high pressure, to show greater 
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levels of transfection in COS-7 and CHO cells compared to electroporation 
and lipofection (lipofection is described in further detail below). After the DNA 
is physically delivered inside the cell it is gradually released inside the cell 
post-bombardment (Mehier-Humbert & Guy, 2005). The technique has been 
used to propel DNA coated beads into the epidermal layer for the genetic 
immunization of skin, however, the depth of penetration is shallow, limiting the 
region to which DNA is delivered (Mehier-Humbert & Guy 2005).  
1.1.2.2 Chemical Methods 
 
Calcium-phosphate 
 
One of the simplest chemical transfection methods devised to date is to form 
complexes of DNA co-precipitated with calcium phosphate (Song & Lahiri, 
1995), which is both simple and inexpensive and utilizes the basic procedure 
of Graham and van der Eb (Wilson et al., 1995). Calcium phosphate-DNA 
particles are formed electrostatically (Mozafari & Omri 2007) by mixing DNA 
and calcium phosphate in buffer and then incubating the resulting complexes 
with target cells (Song & Lahiri, 1995). The calcium phosphate is thought to 
provide a stabilizing function to the nucleic acids (Mozafari & Omri 2007), 
which are uptaken into cells by endocytosis. It has been suggested that the 
presence of calcium phosphate results in an osmotic imbalance inside the 
endosome, causing complex release into the cytoplasm (Mozafari & Omri, 
2007).  
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However, despite optimization of several of the parameters involved in 
precipitate formation, including the pH of the precipitate forming solution, the 
concentrations of calcium and phosphate and the incubation time of cells with 
the precipitate (Wilson & Smith, 1997), transfection rates achieved are still 
much lower than those attained using viral vectors, even when additional 
agents such as glycerol are included in the medium to improve rates of 
transfection (Wilson et al., 1995). An additional problem with the calcium 
phosphate technique is that the precipitates formed are unstable and must be 
made fresh to avoid nano-sized crystals aggregating to form micro-sized 
crystals, which renders them too large to be endocytosed (Mozafari & Omri, 
2007) and although this problem can be circumvented by coating the particles 
with a surrounding layer of poly(ethylene glycol) (PEG) or even another coat 
of calcium phosphate (Sokolova et al., 2006), the technique as a whole 
remains limited for in vivo applications because of DNase I degradation of the 
complexes and because the complexes interact unfavourably with serum 
proteins, causing aggregation and increases in particle sizes (Mozafari & 
Omri 2007). 
 
Liposomes 
 
Complexing cationic lipids, or liposomes, with DNA is simple because 
positively charged lipids and negatively charged DNA spontaneously form 
complexes (lipoplexes) through ionic interactions (Felgner et al. 1987).  
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Following an initial rapid interaction between liposomes and DNA through 
electrostatic interaction, a slower lipid rearrangement process occurs 
(Pedroso de Lima et al. 2001).  
 
The simplest way to prepare lipoplexes is to mix diluted solutions of 
preformed liposomes with plasmid DNA, which yields heterogeneously sized 
lipoplexes with a similar morphology (Gao et al. 2007). However, an 
alternative approach is to mix a DNA-containing solution directly onto a dried 
film of cationic lipid and DOPE (Hofland et al. 1996). The latter approach 
entraps DNA within multilamellar liposomes rather than sandwiching DNA 
between liposomes (Hofland et al. 1996). Thus, liposomes can form one of 
two structures with DNA – either a spherical, smooth surface structure, in 
which DNA is entirely wrapped within the liposome (Wasungu & Hoekstra, 
2006), or a flat structure in which DNA strands are intercalated between lipid 
bilayers into a multilamellar structure (Rädler et al. 1997). 
 
Following DNA binding, complexes that maintain a net positive charge are 
then able to interact with negatively charged cell membranes (Ourlin et al. 
1997) to be uptaken through either endocytosis (Li & Huang, 2000; Mozafari 
& Omri, 2007, Wasungu & Hoekstra, 2006) or alternatively by membrane 
fusion (Mozafari & Omri, 2007; Ourlin et al. 1997) (see Fig. 1 below).  It has 
been suggested that DNA is released from liposomes once inside the cell 
because of an interaction between cationic liposomes and anionic cell lipids, 
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leading to charge neutralization and the release of DNA from the complex 
(Gardlik et al., 2005; Mozafari & Omri, 2007). In liposome-based transfection, 
DNA is released from the liposome prior to nuclear entry (Xu et al. 1996) and 
for successful transfection, must then be trafficked to the nucleus, the ultimate 
site of action for subsequent gene expression (Shenoy & Amiji, 2007). It is 
this transport of DNA to the nucleus that has proven the critical barrier to 
success using liposomal transfection (Dunlap et al., 1997). 
 
A number of liposome formulations have shown enough promise during in 
vitro studies to warrant evaluation in clinical trials for the treatment of cystic 
fibrosis. DOTAP [1,2-bis(oleoyloxy)-3-(trimethylammonio)propane], first 
described by Leventis & Silvius (1990), demonstrated reduced toxicities 
because the ester bonds it possessed, linking the cationic head group to the 
lipid anchor, facilitated degradation in eukaryotic cells. However, DC-
Chol{3b[N-(N´,N´-dimethylaminoethane)-carbamoyl]cholesterol} mixed with 
DOPE, first described by Gao & Huang (1991), remains the most widely used 
lipid in cystic fibrosis clinical trials as it shows even lower toxicities still. The 
use of cholesterol, which stabilizes lipid bilayers, rather than hydroxyalkyl 
chains as the lipid anchor, meant not only were toxicities reduced with DC-
Chol, liposome stability was improved and effectiveness was enhanced. Lipid 
GL-67TM has a similar structure to DC-Chol but has a triple amine head-group 
rather than a single amine head. However, despite its increased transfection 
efficiencies, Lipid GL-67TM appeared to cause greater pulmonary toxicity than 
 17 
DC-Chol (Lee et al. 2005). Summarising the effects of polymer structure on 
transfection efficiency, Lee et al. (2005) conclude that trivalent cationic head-
groups were more effective than equivalent monovalent, bivalent or 
quadrivalent lipids. Also, carbamate linkers and cholesterol anchors appeared 
most effective when compared with alternative structures. 
 
 
Figure 1: A: uptake of liposomes through membrane fusion – liposomes fuse with the plasma 
membrane and deliver their DNA payload directly into the cytoplasm. DNA must then be 
trafficked to the nucleus for transcription to take place. B: uptake of liposomes through 
endocytosis. Cells ingest the liposome/DNA complex within the plasma membrane, which 
encircles the lipoplex before pinching off to entrap the lipoplex within an endosome. The 
Cationic liposome + 
Plasmid complex 
Cell 
Nucleus 
Endocytosis 
Degradation in 
 lysosomes 
B 
Cationic liposome + 
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Membrane fusion 
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Nucleus 
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lipoplex must then escape the endosomal compartment to avoid lysosomal degradation, and 
must then be trafficked to the nucleus for transcription to take place. Redrawn from Lee et al. 
(2005). 
 
One of the reasons why many liposome formulations are more effective in 
vitro than in vivo is because there is plethora of negatively charged and often 
amphipathic proteins in polysaccharides present in the blood, mucus, 
epithelial lining fluid or tissue matrices to which a candidate transfection 
vector would not be exposed to in vitro (Gao et al. 2007). In the presence of 
such components, dramatic changes in size, surface charge and lipid 
composition of liposomes are observed (Gao et al. 2007). Additionally, when 
administered in vivo, many lipoplexes never even reach their intended target 
as they interact with negatively charged blood components, forming large 
aggregates which are absorbed onto the surface of red blood cells or become 
trapped in a thick mucus layer for example (Gao et al. 2007). 
 
Polyplexes 
 
The potential of polymers as an alternative to liposomes for gene delivery has 
long been known. Wu & Wu (1988) used poly-L-lysine DNA vectors to deliver 
SV2 CAT plasmid DNA to rat liver cells and a whole host of other polymers 
have since been used to achieve transfection.  
 
Polymers used in the past to achieve gene delivery include cationic polymers 
such as chitosan (Strand et al. 2005; Zhao et al. 2006), gelatin (Kaul & Amiji, 
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2004; Leong et al. 1998), poly(ethyleneimine) (PEI) (Bertschinger et al. 2006; 
Feng et al. 2006; Nimesh et al. 2006) and poly(ethylene glycol) (PEG) (Jang 
et al. 2006) but also non-ionic polymers such as poly(lactic-co-glycolic acid) 
(PLGA) (Tinsley-Bown et al. 2000;) and non-condensing polymers such as 
poly(vinyl pyrollidone) (PVP) (Jang et al. 2006; Mumper et al. 1996; Mumper 
et al. 1998) and poly(vinyl alcohol) (PVA) (Mumper et al. 1996; Mumper et al. 
1998; Wittmar et al. 2005).  
 
Polymers designed for gene delivery must fulfill several biological functions 
including encapsulating DNA and stabilizing it by providing a protective 
hydrophilic polymer coating (Shenoy & Amiji, 2007). Once uptaken by cells, 
vectors must release the genetic material and facilitate its transport to the 
nucleus – the ultimate site of action for genetic expression (Shenoy & Amiji, 
2007). 
 
Although cationic polymers remain the most commonly used as they have a 
higher DNA encapsulation efficiency than neutral polymers (the low 
encapsulation efficiency of DNA in non-ionic polymers is due to the difficulty 
in incorporating hydrophilic DNA into a hydrophobic polymer), and despite the 
fact encapsulation of DNA with non-ionic polymers requires higher energy 
which denatures some of the DNA (Jang et al. 2006), Mumper et al. (1996) 
have shown that neutral, non-condensing polymers such as PVA can still bind 
to DNA and afford it a level of protection from nucleases, achieving improved 
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distribution in rat tibialis muscle compared to plasmid administered in a saline 
solution. 
 
PVA is an amphiphilic molecule with a hydrophobic backbone and hydrophilic 
side chains and acts as a hydrogen bond donor. As it is charge neutral it 
stabilizes DNA through hydrogen bonding and/or van der Waals forces rather 
than charge neutralization - as is the case with cationic polymers (Holtorf & 
Mikos, 2002), which form complexes with DNA spontaneously in solution 
through electrostatic interactions between negatively charged phosphate 
groups on the DNA and the positively charged groups of the polycation (Jang 
et al. 2006). 
 
The number of authors reporting successful transfection with PVA 
nanoparticles, relative to commonly used polymers such as 25 kDa PEI, 
remains small, with only a handful of papers reporting successful transgene 
expression following transfection with PVA nanoparticles. In addition to 
papers by Mumper et al. (1996) and Mumper et al. (1998) - which described 
in vivo transfection in rat skeletal muscle - Wittmar et al. (2005) have reported 
successful transfection with amine-modified PVA vectors. However, 
transgene expression was only noted when transfections were performed in 
the presence of an endosome disruptor, chloroquine (Wittmar et al. 2005), 
despite the fact cellular uptake of nanoparticles had been reported, 
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suggesting that an inability to escape the endosomal compartment may have 
been responsible for the lack of reporter gene expression observed.  
 
Those findings were consistent with those previously described by Kimura et 
al. (2004), who fluorescently labelled pDNA with rhodamine and formed 
subsequent complexes through ultra high pressure technology with four 
different PVA‟s which differed in their degree of polymerization and 
saponification. Those PVA‟s with higher degrees of saponification (98.5 %, 
99.3 % and 99.8 %) were better internalized into the Raw264 cell line, whilst 
the PVA with an 88 % degree of saponification did not appear to have been 
internalized into cells.  
 
Fig 2. – schematic illustration of the process involved in gene expression. Redrawn from 
Maitra (2005). 
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Nevertheless, in all cases, no reporter gene expression was reported from the 
study because it would appear, as in one of the possible fates for an 
internalized vector in Figure 2 above, that the plasmid encapsulated in the 
nanoparticles in question had failed to escape the endosome and was 
degraded by the lysosome rather than being trafficked to the nucleus.  
 
An intracellular trafficking study undertaken by Godbey et al. (1999) yielded 
important results for workers in the field as it identified the pathway 
fluorescently labelled polyplexes complexes take during transfection. Doubly-
labeled PEI/DNA complexes attached to the cell membrane at discrete 
locations, suggesting endocytosis as the route of entry in cells, after 30 
minutes. Nuclear localization was noted 3.5 - 4.5 hours after polyplexes had 
been administered to cells, however, transgene expression was not noted 
until a further hour later (Godbey et al. 1999). In some instances, large 
aggregations of fluoresecence were noted, indicating polyplexes had become 
trapped inside intracellular vesicles, whilst in other cases, polyplexes could 
freely disperse in the cytoplasm after endosomes or endolysosomes had 
been disrupted (Godbey et al. 1999). As both Kimura et al. (2004) and 
Wittmar et al. (2005) reported cellular uptake of PVA nanoparticles but failed 
to report transgene expression, it would appear that in both instances the lack 
of gene expression was a result of inefficient endosomal escape. The fact 
Wittmar et al. (2005) reported gene expression only when transfections were 
performed in the presence of chloroquine further reinforces this conclusion.  
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Perhaps the most active and most studied polymer for gene delivery system 
is poly(ethyleneimine) (PEI) (Gao et al. 2007). The success of PEI in 
comparison to other polymers stems from the fact that it possesses an inbuilt 
mechanism for endosomal escape and thus is avoids lysosomal trafficking 
(Akinc et al. 2005). PEI is only partially protonated at physiological pH (only 
one of six amino nitrogens) and thus, upon acidification within the endosome, 
PEI presumably acts as a proton sponge, with an influx of protons into the 
endosome occurring. To ensure charge neutrality, chloride ions are pumped 
into the endosome at the same time which increases the ionic strength of the 
medium, and this leads to osmotic swelling and destabilization of the 
endosomal vesicle (Akinc et al. 2005).  
 
Akinc et al. (2005) have used proton pump inhibitors and N-quaternized forms 
of PEI and shown that transfection efficiency is reduced by two orders of 
magnitude, and can only be increased if chloroquine, an endosome disruptor, 
is included in the transfection medium. Chloroquine is a weak base, FDA 
approved for the treatment of malaria (Pack et al. 1999), and is often used at 
a final concentration of 100 µM in transfection media (Akinc et al. 2005; 
Leong et al. 1998; Reschel et al. 2002) to buffer the endosome to maintain a 
neutral endosomal pH and is able to improve rates of transfection in two 
ways. Firstly, it reduces the activity of the lysosomal nucleases and secondly, 
the buffering it provides may produce expansion of the internalized vector, 
leading to subsequent destabilization of the endosome (Wiethoff and 
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Midaugh, 2002). However, it is impractical for in vivo gene therapy because it 
is toxic to many cell types in vitro and, in high doses, may lead to a variety of 
undesirable side effects (Pack et al., 1999). As a consequence, developing a 
vector that does not rely on chloroquine for endosomal escape is desirable. 
Although glycerol, which presumably increases transfection efficiency by 
interfering with lysosomal degradation and increasing DNA released into the 
cytoplasm (Wagner, 1998) and is typically used at a concentration of 1 – 1.8 
M (Zauner et al., 1996), and inactivated adenoviruses have also been used 
for the same purpose (Wagner et al., 1992), both are also equally undesirable 
for in vivo applications - high local concentrations of glycerol that would be 
required to bring about improvements in transfection efficiency whilst 
inactivated adenovirus particles, although they appear non-toxic in vitro, 
would be expected to be immunogenic and add an extra step to the vector 
synthesis procedure (Pack et al. 1999).  
 
Although Oster et al. (2004) have shown that chemically modifying PVA can 
lead to successful transfection - grafting PLGA onto the PVA backbone 
produced nanoparticles that transfected L929 mouse fibroblast cells eight 
times more effectively than PEI – PVA has also been used during transfection 
studies when used as an emulsifier (Panyam et al. 2002; Prabha & 
Labhasetwar, 2004) or a stabilizer (Li et al. 2003; Perez et al. 2001) in the 
production of polyplexes between DNA and another polymer, rather than as 
the main constituent of a nanoparticle. 
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For example, Li et al. (2003) have reported that adding PVA to a plasmid 
DNA-containing solution during encapsulation with PEGylated 
polycyanoacrylate nanoparticles can reduce pDNA damage, although Prabha 
& Labhasetwar (2004) note that the levels of reporter gene expression 
observed are dependent upon the molecular weight and degree of 
hydrolysation of the PVA used as an emulsifier. 
 
Perhaps the most successful examples of gene delivery using PVA have 
been achieved when the polymer has been used to coat superparamagnetic 
iron oxide nanoparticles (SPIONSs) with which cells are incubated with in the 
presence of a magnetic field during transfections. Petri-Fink et al. (2005) have 
synthesized PVA-coated SPIONs with a mean diameter of 9 mm, with various 
ratios to iron oxide of either PVA, carboxylate-functionalised PVA, thio-
functionalised PVA and amino-functionalised PVA. Their results showed only 
amino-PVA coated SPIONS were uptaken in an interesting amount of the four 
SPION preparations tested. 
 
Kamau et al. (2006) have also demonstrated high levels of gene expression 
using PVA or coated SPIONs, further functionalized with amino groups and 
fluorochromes, to transfect synovial cells in the presence of a magnetic field. 
PVA nanoparticles were uptaken by more then 80 % of synovial cells, whilst 
GFP expression was detected in 17.7 % of 293 T cells. In comparison, PEI 
coated SPIONS produced transfection in 43.5 % of 293 T cells and produced 
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a GFP signal of higher intensity which was visible after 24 hours, rather than 
48 hours as in the case of PVA. PVA nanoparticles were less toxic, however. 
Thus, Kamau et al.‟s (2006) results suggest either a difference in particle 
uptake by the cells for the two different polymers or different release in DNA 
release from these polymers. 
 
Lastly, DNA release from PVA nanoparticles can be controlled by the 
nanoparticle production method, as shown by Kimura et al. (2007). 
Complexes between PVA and DNA were formed either through UHP 
technology or freeze thaw methods and their DNA release profiles were 
compared, with less DNA released by the pressurized hydrogels. The 
cumulative amount of DNA released decreased as the PVA content of the 
hydrogels increased, whilst varying the amount and duration of pressure used 
to form hydrogels can also influence DNA release (Kimura et al. 2007). 
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1.2 Materials and Methods 
1.2.1 Abbreviations, reagents and materials 
Abbreviations Supplier/code (if 
applicable) 
PBS Phosphate Buffered Saline Sigma, UK 
P3813 
HBSS Hanks Balanced Salt Solution Promocell, Germany 
C-40390 
RPMI 1640  Roswell Park Memorial Insititute 
(cell culture medium) 
Promocell, Germany 
C-76015 
Advanced 
DMEM  
Advanced Dulbecco‟s Modified 
Essential Medium 
GIBCO, UK 
12491 
DAPI 4',6-diamidino-2-phenylindole A constituent of 
Vectashield mounting 
medium 
PVA poly(vinyl alcohol)  
PEI poly(ethyleneimine)  
PEG poly(ethylene glycol)  
DOTMA {N-[1-(2,3-dioleyloxy)propyl]-
N,N,N,-trimethylammonium 
chloride} 
 
DOPE (dioleoyl 
phosphatidylethanolamine) 
 
DOSPA  {2,3-dioleyloxy-N-
[2(sperminecarboxamido)ethyl]-
N,N-dimethyl-l-propanaminium 
trifluoroacetate} 
 
DOTAP  [1,2-bis(oleoyloxy)-3-
(trimethylammonio)propane] 
 
DC-Chol  {3b[N-(N´,N´-
dimethylaminoethane)-
carbamoyl]cholesterol} 
 
PLGA poly(lactic-co-glycolic acid)   
PVP poly(vinyl pyrollidone)   
PD2000 Patented cross linker used by 
AGT Sciences Ltd in nanoparticle 
production 
 
pEGFP-N1 Plasmid DNA used in the project, 
coding for green fluorescent 
protein, under the control of a 
cytomegalovirus promoter 
 
DH5-αTM Strain of Escherichia coli that was Kindly provided by Dr. 
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transformed with the plasmid Steven Picksley, 
University of Bradford, 
UK. 
NIH 3T3  Mouse embryonic fibroblast cells 
used during transfection studies 
Kindly provided by 
Debbie Fischer 
University of Bradford, 
UK. 
HaCaT Keratinocyte cells used during 
transfection studies 
Kindly provided by Dr. 
Annie Smith, 
University of Bradford, 
UK. 
POVAL Hydrogel formulation used to 
produce nanoparticles, 99 % 
hydrolysed 
 
KP-08 Hydrogel formulation used to 
produce nanoparticles, 80 % 
hydrolysed 
 
EtBr Ethidium Bromide Fluka, UK 
46067 
TAE Tris-acetate EDTA buffer solution Invitrogen, UK 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Sigma, UK 
H0887 
FCS Foetal calf serum Promocell, Germany 
C-37360 
NCS Newborn calf serum Sigma UK 
N4762 
LB broth/agar Luria-Bertani broth/agar  
GFP Green fluorescent protein  
 Chloroquine Sigma, UK 
C6628 
 Kanamycin Sigma, UK 
K1377 
 Ampicillin  Sigma, UK 
A0166 
 Tween 20 Sigma UK, 
P-7949 
 Amphotericin B (fungizone) Sigma UK, 
A2942 
 Optimix solution (electroporation 
buffer) 
Equibio, UK 
 Lipofectin® Invitrogen 
18292-011 
 LabelIT® Tracker Intracellular 
Nucleic Acid Localisation Kit 
Mirus Bio Corp, USA 
MIR 7013 
TAE tris-acetate EDTA buffer solution Invitrogen, UK 
15558 
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 Electrophoresis Grade Agarose Invitrogen, UK 
15510 
 Trypsin-EDTA Sigma, UK 
T 4049 
Table 1 – Abbreviations, reagents and materials and source of supply 
 
All hydrogel nanoparticles used during the project were synthesised and 
provided by AGT Sciences Ltd, Bradford, UK in distilled water as a 10 mg/ml 
colloidal suspension. Nanoparticles were synthesised from PVA and were 
crosslinked with AGT Sciences‟ patented cross-linker, PD2000, giving the 
nanoparticles a positive charge. The main hydrogel formulation evaluated 
during the project was „KP-08‟, which contains 30 % residual acetate and is 
thus more hydrophobic than the „POVAL‟ formulation which was later 
evaluated. POVAL contains less than 1 % residual acetate and thus its 
surface is less hydrophobic compared to KP-08. 
1.2.2 General Methods 
 
In order to provide a source of cells for transfection experiments, cell culture 
work was first undertaken to establish and maintain cell lines that could 
readily provide cells when required. Microbiological work was also undertaken 
to transform competent DH5-αTM Escherichia coli (E. coli) to uptake reporter 
plasmid DNA encoding enhanced green fluorescence protein (EGFP-N1). 
The transformed E. coli were then cultured on a large scale to yield large 
amounts of the EGFP-N1 plasmid which was subsequently purified on a large 
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scale using an endotoxin-free gig-prep kit (Qiagen, UK) for use in hydrogel 
binding and transfection experiments. 
 
1.2.2.1 Cell Culture 
 
Three types of cells were used on the project – HaCaTs (spontaneously 
transformed human keratinocytes), NIH 3T3‟s (mouse embryonic fibroblasts) 
and neonatal articular chondrocytes (isolated from mice). Experiments 
switched to using different cell types for transfection at various points during 
the project as certain cell types have proven more difficult to transfect than 
others in the literature. 
 
HaCaT cell culture  
 
HaCaT cells were cultured in RPMI media, fully supplemented with 10 % (v/v) 
FCS, 2 mM U/ml L-Glutamine, 100 U/ml penicillin-streptomycin and 1 µg/ml 
amphotericin B. Cells were cultured in either T-25 or T-75 cell culture flasks 
and incubated at 37ºC in a 5 % CO2 atmosphere and split once they had 
reached 70 % confluence.  
 
NIH 3T3 cell culture 
 
NIH 3T3 cells were grown in advanced DMEM fully supplemented with 5 % 
(v/v) NCS, 20 mM U/ml L-Glutamine, 100 U/ml penicillin-streptomycin, 1 
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µg/ml amphotericin B and 20 nM HEPES. Cells were cultured in either T-25 or 
T-75 cell culture flasks and incubated at 37ºC in a 5 % CO2 atmosphere until 
they had reached 70 % confluence.  
 
Chondrocyte cell culture  
 
Articular chondrocytes obtained from neonatal mice (passage one) were 
kindly provided by Dr. Abbas Din (AGT Sciences Ltd, Bradford, UK) and 
cultured in RPMI media, fully supplemented with 10 % (v/v) FCS, 2 mM U/ml 
L-Glutamine, 100 U/ml penicillin-streptomycin and 1 µg/ml amphotericin B. 
Cells were cultured in either T-25 or T-75 cell culture flasks and incubated at 
37ºC in a 5 % CO2 atmosphere and split once they had reached 70 % 
confluence.  
 
Upon reaching confluence cells were briefly washed with HBSS and then 
trypsinised using 4ml (T-25) or 8ml (T-75) trypsin-EDTA. The enzymatic 
activity of trypsin was neutralised using 0.125 volumes of fully supplemented 
cell culture media and cells were then centrifuged in a Hettich Rotofix 32 
centrifuge at 2000 rpm for 5 minutes. Cell pellets were then re-suspended in 
an appropriate volume of the appropriate cell culture media (fully 
supplemented) and were plated back out into T-25 or T-75 cell culture flasks 
containing appropriate cell culture media. 
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1.2.2.2 Plasmid Purification 
 
A stock of pDNA was obtained through four steps which are subsequently 
described; 
 
1. Preparing competent DH5-αTM E. coli cells 
2. Purifying small (µg) quantities of pEGFP-N1 from previously 
transformed     E. coli 
3. Transforming the E. coli from step 1 with the pEGFP-N1 obtained in 
step 2 
4. Culturing the transformed E. coli from step 3 on a large-scale sufficient 
to yield (mg) quantities of pEGFP-N1 from plasmid  purification. 
 
Preparation of competent cells 
 
Using a sterile inoculating loop, DH5-αTM E. coli were transferred from a 
frozen glycerol stock and streaked out onto a Luria-Bertani (LB) agar plate 
lacking antibiotics. A control plate was also prepared by streaking out E. coli 
onto a kanamycin selective (50 µg/ml) LB agar plate. Both plates were then 
incubated at 37 ºC for 24 hours to promote bacterial growth, after which time 
they were stored, inverted, at 4ºC in the fridge. 
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Preparation of pEGFP-N1 DNA 
 
Plasmid DNA was purified from previously transformed DH5-α E. coli using a 
mini-prep plasmid purification kit (Qiagen, UK) to yield 20 µg of pDNA that 
could be incorporated into E. coli during transformation.  
 
Previously transformed E. coli containing the pEGFP-N1 plasmid were 
streaked out from a frozen glycerol stock onto a kanamycin (50 µg/ml) 
selective agar plate. Control plates were also prepared by streaking out E. 
coli onto ampicillin selective (100 µg /ml) and plain agar plates. All plates 
were then incubated at 37ºC for 24 hours to promote bacterial growth. 
 
The following day a single colony of the transformed bacteria was inoculated 
into 5 ml of LB broth supplemented with 50 µg/ml of kanamycin in a 15 ml 
falcon tube. A falcon tube containing LB broth only was used as a negative 
control and for subsequent spectrophotometric readings. Both cultures were 
grown overnight at 37 ºC with moderate shaking at 180 rpm in an orbital 
shaker. 
 
The following morning, 1.5 ml of the overnight culture was transferred into two 
separate 1.5 ml eppendorf tubes and centrifuged at 13,000 rpm for 1 minute 
in an MSE Micro Centaur table top centrifuge to obtain a bacterial pellet. The 
bacterial pellets were combined into one tube by re-suspension in 250 µl of 
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buffer P1 after supernatants had been discarded, and the plasmid purification 
procedure was followed according to manufacturer‟s instructions. In the final 
step of the procedure, plasmid DNA was eluted into 50 µl of EB buffer and the 
DNA concentration was determined spectrophotometrically by diluting 5 μl of 
the DNA stock 1:200 in EB buffer to a final volume of 1 ml in a quartz cuvette 
and measuring the absorbance reading at 260 nm. Purified DNA was then 
stored at -20°C until required. 
 
Transformation of cells 
 
An isolate from a streaked plate of untransformed bacteria was then 
inoculated into 5 ml of LB broth in a 15 ml falcon tube and also into 5 ml of LB 
broth containing 50 µg/ml kanamycin (positive control). A negative control 
was also prepared by transferring 5 ml of LB broth into a separate falcon tube 
but adding no bacteria.  Both tubes were then incubated at 37ºC in an orbital 
shaker with moderate shaking at 180 rpm overnight.  
 
100 µl of overnight culture was then inoculated into 10 ml of LB medium 
(1:100 dilution) in 50 ml falcon tubes and then incubated in an orbital shaker 
at 37ºC with shaking of 180 rpm until an OD650nm of 0.3-0.4 (mid-log phase) 
had been reached. 
 
1 ml of the bacterial culture was then transferred into two separate 1.5 ml 
eppendorf tubes (one to act as a negative control), which were then 
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centrifuged at 13,000 rpm for 1 minute at room temperature in a MSE Micro 
Centaur table-top centrifuge. 
 
The supernatant was decanted from each tube and each pellet was re-
suspended in 800 µl of ice cold 0.1 M CaCl2 solution. Both tubes were held on 
ice for 20 minutes and then centrifuged as before. Supernatants were 
discarded and each pellet was re-suspended in 400 µl of ice cold 0.1 M CaCl2 
solution and held on ice for 10 minutes. 
 
Both solutions were then centrifuged again, as above, and re-suspended in 
200 µl of 0.1 M CaCl2 solution. 200 µl of each solution was then transferred 
into two new 1.5 ml eppendorfs. 5 µl of pEGFP-N1 pDNA was then added to 
one of the tubes, which was tapped gently to mix the solution, and then both 
tubes were held on ice for 30 minutes.  
 
The bacteria were then heat shocked by submerging them into a 42°C water 
bath for 45 seconds followed by a further 5 minutes of incubation on the 
bench top on ice. 1 ml of LB broth was then added to each tube, mixed by 
inverting the tube, and then incubated at 37°C for 45 minutes in an orbital 
shaker set to 200 rpm to allow expression of the kanamycin resistance 
protein. 200 µl of the bacterial suspension was then transferred onto agar 
plates containing either LB agar alone, kanamycin (50 µg/ml) or ampicillin 
(100 µg/ml) using sterile spreaders. 200 µl of the control suspension lacking 
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pDNA was also transferred onto plates containing either LB agar alone or 
kanamycin (50 µg/ml). Plates were left to dry on the bench top for a few 
minutes and then inverted and incubated overnight at 37°C. 
 
The following day a single colony was isolated from the LB-selective plate, 
inoculated into 5 ml of LB broth containing 50 µg/ml kanamycin in a 15 ml 
falcon tube, and grown overnight. The following morning, 800 µl of the 
overnight culture was then mixed with 200 µl of sterile 80% glycerol and 
frozen down in screw top vials at -20ºC. This provided a long-term stock of 
transformed bacteria that could be defrosted, cultured and harvested for the 
plasmid during the project whenever required.  
 
Large – Scale Plasmid Purification 
 
Plasmid DNA was purified from previously transformed DH5-α E. coli on a 
large scale using an EndoFree Giga-prep plasmid purification kit (Qiagen, 
UK).  
 
Using a sterile inoculating loop, transformed E. coli were streaked out onto 
agar plates containing either kanamycin 50 µg/ml, ampicillin 100 µg/ml or LB 
agar alone. The plates were left on the bench top for a few minutes to dry and 
were then incubated at 37ºC for 24 hours. 
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The following day a single colony of bacteria from the kanamycin selective 
plate was inoculated into a starter culture of 10 ml of LB broth containing 50 
µg/ml of kanamycin and grown in an orbital shaker at 37ºC with 200 rpm, for 8 
hours.  
 
1 ml of the starter culture was then transferred into each of four 2 litre conical 
flasks, each containing 500 ml of LB broth supplemented with 50 µg/ml of 
kanamycin. All flasks were then transferred to an orbital shaker set to 200 
rpm for 16 hours growth at 37ºC. 
 
The following day the cultures were centrifuged using a Beckman Coulter 
Avanti J-25 centrifuge equipped with a JLA 10.500 rotor pre-cooled to 4ºC. 
Cultures were spun at 6000 x g for 15 minutes at 4ºC to avoid overheating of 
the samples. All supernatant was re-collected for autoclaving, whilst the wet 
pellet weight of the culture was determined to ascertain bacterial density. 
 
The bacterial pellet was then re-suspended in 125 ml of buffer P1 and the 
plasmid purification procedure was followed according to manufacturer‟s 
instructions. Centrifugation during the latter stages of the procedure was 
conducted on a Beckman Coulter Avanti J-25 centrifuge equipped with a JA 
25.50 rotor. Again, centrifugation was performed at 4ºC to avoid overheating 
of the samples and was performed at 18,000 x g for the necessary time 
intervals. 
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In the final purification step, pDNA was dissolved in endotoxin free TE buffer 
or sterile distilled water, and the pDNA concentration was determined 
spectrophotometrically on three spectrophotometers by reading the 
absorbance at 260 nm. pDNA was adjusted to an appropriate concentration 
and then aliquotted into eppendorf tubes for long term storage at -20ºC. 
Lastly, DNA quality was determined via electrophoresis by running a 1 µg 
sample of the purified plasmid on an agarose gel. 
 
1.2.2.3 Rhodamine-labelling of pDNA 
 
For intracellular tracking of pDNA during transfection, µg quantities of pDNA 
were labelled with rhodamine using a LabelIT® tracker TM-rhodamine 
labelling kit according to manufacturer‟s instructions and using a Heraeus 
bench-top mini centrifuge pre-cooled to 4 ºC. 
 
After rhodamine-labelled plasmid had been pelleted in the final step following 
ethanol precipitation, the stock of labelled plasmid was re-suspended in 
sterile distilled water in 2 µg aliquots ready for transfection when required.  
 
1.2.2.4 Polyplex formation 
 
To synthesise polyplexes the required amount of hydrogel (typically 40 µl of a 
10 mg/ml stock: 400 µg of hydrogel) was mixed with a 2 µg aliquot of pDNA 
(re-suspended in 25 µl of sterile distilled water) in 1.5 ml eppendorf tubes, 
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mixed by tapping the bottom of the tube, and incubated at room temperature 
for 15 minutes.  
 
For electrophoresis experiments the polyplexes formed were typically diluted 
into HBSS, PBS or cell culture media such as RPMI 1640, advanced DMEM 
or Opti-MEM to test the stability of the complexes in buffered solutions.  
 
For transfection experiments, polyplexes (typically of volume 65 µl, with 2 µg 
of pDNA in each sample) were diluted in a final volume of 2 ml of Opti-MEM 
media and incubated at room temperature for at 5  minutes before being 
added to cells. 
 
1.2.2.5 Agarose Gel Electrophoresis 
 
Samples were prepared by mixing 20 µl of solution with 5 µl of gel loading 
buffer (a 50:50 mix of sterile glycerol and distilled water) before being loaded 
into the agarose gel. The presence of the loading buffer added density to the 
sample to prevent samples floating out of the wells. However, bromophenol 
blue, which is typically included in loading buffers so that DNA fragments can 
be visually tracked during electrophoresis, was omitted from the loading 
buffer to prevent any possible interaction the dye may have had with the 
hydrogel nanoparticles in each sample.  
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Electrophoresis was performed on 0.8 % (w/v) agarose gels made up using 
molecular biology grade agarose dissolved in 1 X TAE buffer using a 
microwave oven. For some experiments 0.5 µg/ml ethidium bromide (EtBr) 
was incorporated into the cast gel whilst in others, gels were cast without EtBr 
and then subsequently stained in a small plastic box filled with 400 ml of 1 X 
TAE containing 0.5 µg/ml EtBr. In the latter case, gels were soaked for 30 
minutes and agitated periodically before being briefly rinsed under a cold 
water tap to remove excess dye. Omitting EtBr from the gels and staining 
them after the samples had been run in the electrophoresis tank improved the 
resolution of the subsequent image produced; however, it lengthened the time 
taken for each experiment.  
 
For electrophoresis, agarose gels were placed into Bio Rad sub-cell tank 
linked to a Bio-Rad Power Pac 200 power supply and run at 90 V for 90 
minutes. After this time gels were stained in an ethidium bromide solution if 
required and then transferred under a UV light box to be photographed using 
UVI photo imaging software. 
 
For each experiment a sample of free pDNA, which was re-suspended in 
distilled water but unattached to any vector, and a DNA ladder (Hyperladder I 
DNA, Bioline, USA) were included in separate lanes on each agarose gel. 
The inclusion of free DNA allowed a comparison to be made with DNA mixed 
with hydrogel in polyplex samples. The presence of the DNA ladder, which 
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contained DNA fragments of known length, allowed an estimate of the size of 
the DNA fragments in each sample to be made. By mixing the DNA ladder 
with a loading buffer containing bromophenol blue it was possible to visually 
track the movement of the DNA fragments across the gel. 
 
1.2.2.6 Transfection 
 
On the day preceding transfection, cells were seeded onto glass coverslips 
(Chance Propper, UK), placed inside 35 x 10 mm Petri dishes, typically at a 
density of 1 x 105 cells per dish (cell counts were determined using a 
Neubauer haemocytometer). Cells were incubated for 15 mins at 37 ºC in a 5 
% CO2 atmosphere to allow cell attachment and then an additional 2 ml of the 
appropriate cell culture media was added to each dish. Cells were then grown 
overnight at 37 ºC in a 5 % CO2 atmosphere, giving rise to a cell layer that 
was around 70 % confluent on the day of polyplex addition. 
 
During transfection, cells were transfected with polyplexes diluted into Opti-
MEM cell culture medium, typically in the absence of serum, over a 5 hour 
period. A negative control of free pDNA diluted into Opti-MEM media was also 
included into each transfection experiment, as was a positive control 
comprised of Lipofectin® complexed with 2 µg of pDNA according to 
manufacturer‟s instructions. 
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When the transfection period had elapsed, polyplex containing solutions were 
aspirated off cells and a media change, with fully supplemented media, was 
performed. Cells were typically grown for a further 43 hours post-transfection 
before being washed three times with PBS-T for five minutes for each wash at 
37ºC. After the third wash, cells were fixed with cell fixing solution (4 % 
paraformaldehyde (w/v) in PBS) for 30 minutes at room temperature and then 
washed with PBS-T a further three times, again with 5 minutes for each wash 
at 37ºC.  
 
Coverslips were then inversely mounted onto clean glass slides using 
Vectashield Mounting Medium (containing DAPI) and kept dark in tinfoil until 
analysis to prevent bleaching of the fluorescence signal. Slides were 
analysed on one of two microscopes – a Leitz Dialux 22 microscope 
connected to a Kodak DC290 zoom digital camera for imaging of GFP or 
rhodamine detection or a Nikon Eclipse 80i microscope for GFP, rhodamine, 
or DAPI detection. 
Images taken using the Leitz microscope were taken using Adobe Photoshop 
imaging (version 6) software. Images taken using the Nikon microscope were 
taken using ACT-2U imaging software and were subsequently edited in 
Adobe Photoshop if necessary. 
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1.2.3 Examining the properties of KP-08 Nanoparticles for 
gene delivery 
 
1.2.3.1 Gel mobility shift assay to determine the optimal KP-08/pDNA 
binding ratio  
 
Complexes of KP-08 and pDNA were formed at varying ratios; 6:1, 8:1, 12:1, 
16:1, 24:1, 31:1, 48:1, 63:1, 94:1, 126:1 and 189:1 (µg of hydrogel: µg of 
pDNA) and an agarose gel mobility shift assay for DNA binding was 
performed. This revealed the minimum amount of hydrogel needed to bind all 
DNA in a given sample. 0.53 μg of DNA was used in all samples.  
 
When KP-08 had been mixed with pDNA the final volume of each solution 
was 22.5 μl. 5 μl of loading buffer was then added to each solution before 25 
μl was loaded into an 0.8 % agarose gel, prepared as previously outlined. A 
DNA ladder and a sample of free pDNA (0.53 μg) were also included in 
control lanes. 
 
1.2.3.2 Determining minimum charge needed to bind pDNA and complex 
stability at differing pH through agarose electrophoresis  
 
Five KP-08 solutions with different levels of positive charge were provided; 
„1/.01‟, „1/.02‟, „1/.03‟, „1/.04‟ and „1/.05.‟ 40 µl of each formulation was mixed 
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with 2 µg of DNA and incubated at room temperature for 15 minutes to form 
polyplexes and then diluted into 135 µl Opti-MEM media of differing pH (7.65, 
7.00, 6.42, 6.15, 5.15 or 4.04) for further incubated for 30 minutes at room 
temperature. 20 µl of the diluted polyplex solutions were then mixed with 5 µl 
of loading solution before loading into an 0.8 % agarose gel along with control 
lanes of free DNA and a DNA ladder. 
 
1.2.3.3 Evaluating KP-08 nanoparticles during transfection  
 
NIH 3T3 cells were cultured and prepared for transfection as outlined 
previously. KP-08 polyplexes were formed by mixing 40 µl of 10 mg/ml KP-08 
with 2 µg of pDNA and incubated at room temperature for 10 minutes. 
Polyplexes were produced in duplicate so that transfections could take place 
over either 5 hours or 24 hours and either in the presence of absence of 100 
µM chloroquine. When transfections were performed over 24 hours 5 % NCS 
was included in the transfection media to maintain cell growth. Naked DNA 
controls were also prepared for transfection periods of either 5 hours or 24 
hours (with 10 5 % serum), as were positive controls of Lipofectin®. Cells 
were prepared for analysis post-transfection as described previously. 
 
1.2.3.4 Examining DNA release from KP-08 nanoparticles at different pH 
 
Complexes of KP-08 and pDNA were formed at a ratio of 200:1 in duplicate 
by mixing 80 μl of 10 mg/ml KP-08 with 4 μg of pDNA (total volume 130 μl) 
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and incubating at room temperature for 10 minutes. Eight different solutions 
of Opti-MEM media were then prepared by adjusting the pH to either 7.8, 
7.15, 6.54, 5.93. 5.15, 4.68 or 4.01 and then the KP-08/pDNA complexes 
were diluted with 270 μl of one of the Opti-MEM solutions. Diluted complexes 
were then incubated at room temperature for 30 minutes and then 20 μl of the 
diluted complexes (containing 0.4 μg of pDNA) was mixed with 5 μl of gel 
loading solution before being loaded into an agarose gel.  
 
1.2.3.5 Transfection of KP-08/Lipofectin® chimeric complexes  
 
NIH 3T3 cells were seeded at a starting density of 2.1 x 105 cells per 
coverslip. Cells were grown overnight and then transfected the following day. 
 
Transfection solutions were made up as follows; 
 
1. KP-08/pDNA nanoparticles - 2 μg of pDNA and 40 μl of 10 mg/ml 
KP-08 were mixed together in an eppendorf tube and incubated at 
room temperature for 60 minutes. 
2. „Chimeric‟ nanoparticles - 2 μg of pDNA and 40 μl of KP-08 were 
mixed together in an eppendorf tube and incubated at room 
temperature for 45 minutes. Simultaneously, 5 μl of Lipofectin® was 
diluted into 100 μl of Opti-MEM cell culture medium and also 
incubated at room temperature for 45 minutes. 35 μl of Opti-MEM 
media was added to the KP-08/pDNA containing solution to bring 
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the volume of the solution to 100 μl and then both solutions were 
then mixed together and incubated at room temperature for a 
further 15 minutes. 
 
Lipofectin® and free DNA controls were also prepared as described 
previously, using 2 µg of pDNA for each control. Transfection solutions were 
made in double quantities - half was used for agarose electrophoresis (to 
determine whether DNA had bound to the hydrogel before the addition of 
Lipofectin®), the other half was used in transfection.  In all cases the final 
volume of each transfection solution was adjusted to 2 ml using serum-free 
Opti-MEM media and all cells were transfected over a 5 hour period at 37ºC. 
Cells were prepared for analysis post-transfection as outlined previously. 
 
1.2.3.6 Using rhodamine-labelled pDNA to detect successful vector 
internalisation  
 
KP-08 polyplexes were prepared by mixing 40 µl of KP-08 with a 2 µg aliquot 
of rhodamine-labelled plasmid and incubating at room temperature for 15 
minutes. 
 
A chimeric transfection solution was prepared by mixing a 2 µg aliquot of 
rhodamine-labelled plasmid with 40 µl of KP-08 nanoparticles and incubating 
at room temperature for 45 minutes and simultaneously diluting 5 µl of 
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Lipofectin® into 100 µl of Opti-MEM media. The diluted Lipofectin® was then 
mixed with polyplexes and incubated at room temperature for a further 15 
minutes. 
 
A positive control was made up using Lipofectin® as described previously 
(except this time the stock of DNA was rhodamine-labelled) whilst a free DNA 
control (rhodamine labelled) was also prepared as in previous experiments. 
All transfection solutions were prepared in duplicate to a final volume of 2 ml 
in Opti-MEM media. One set of solutions was analysed immediately after 
transfection, the other was analysed 43 hours post-transfection. When cells 
were ready for analysis they were prepared as outlined previously, and were 
analysed on a Nikon Eclipse 80i microscope. 
 
1.2.3.7 Investigating primary cells as an alternative target cell type  
 
A flask of articular chondrocytes, obtained from neonatal rats, was provided 
by Dr. Din. Chondrocytes (passage 2) cultured in fully supplemented RPMI 
1640 media  were seeded out onto glass coverslips at a density of 1 x 105 
cells per coverslip and grown overnight before transfection. 
 
Transfection solutions were produced by mixing 40 µl of the KP-08 
nanoparticles with either 2 μg of unlabelled pDNA or 2 μg of rhodamine-
labelled pDNA. Control solutions of naked pDNA (unlabelled and rhodamine-
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labelled) were also prepared, as were positive controls of Lipofectin® 
complexed with either unlabelled or rhodamine-labelled pDNA. All 
transfection solutions were brought to a final volume of 2 ml in serum-free 
Opti-MEM media. Cells were transfected over 5 hours at 37ºC and were 
prepared for analysis as outlined previously. 
 
1.2.3.8 Electroporation of HaCaT cells with KP-08/pDNA polyplexes 
 
HaCaT cells cultured in RPMI 1640 media were grown in T-75 tissue culture 
flasks and split upon reaching confluence. Trypsin-EDTA was used to strip 
the cells from the flasks and after the trypsin had been neutralised, cells were 
centrifuged to obtain a cell pellet and then re-suspended in 2.150 ml of Opti-
Mix washing solution A electroporation buffer (Equibio). 50 µl of cell 
suspension was used for calculating cell density using a Neubauer 
haemocytometer and the remaining cell suspension was split into three 700 µl 
volumes in 1.5 ml eppendorf tubes. 
 
A sample of polyplexes was prepared by mixing 40 µl of KP-08 with 2 µg (25 
µl) of pDNA and incubated at room temperature for 10 minutes. The 65 µl 
sample of polyplexes was then added into one of the tubes containing 700 µl 
of cell suspension and was brought to a final volume of 800 µl using Opti-Mix 
electroporation buffer. 
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Control solutions of KP-08 (without DNA) and naked DNA (without KP-08) 
were also prepared. For the KP-08 control, 40 µl of hydrogel nanoparticles 
was added to 700 µl of cell suspension and the final volume of the solution 
was brought to 800 µl using Opti-Mix electroporation buffer. The naked DNA 
control was prepared by adding 2 µg (25 µl) of pDNA to a sample of cell 
suspension, and the final volume was brought to 800 µl using Opti-Mix 
electroporation buffer. 
 
Each 800 µl sample was then separately pipetted into a 0.4 cm 
electroporation cuvette ready for electroporation. Cells were electroporated 
using a Gene Pulser II electroporator (Bio-Rad, USA), with 1.8 million cells 
electroporated in each treatment. Voltage was set to 0.250 kV on the Gene 
Pulser unit, with capacitance set at 1,000 µF for each electroporation. 
 
Once cells had been electroporated the cell suspension was pipetted back 
out of the electroporation cuvette and placed into a Petri dish containing a 
glass coverslip and 2 ml of pre-warmed cell culture media. Cells were then 
grown for 4 hours to allow ample time for attachment to the coverslip, and the 
media was then aspirated off each set of cells and replaced with 2 ml of fresh 
RPMI media. Cells were then grown until the following morning and were 
analysed 20 hours post-transfection. Cells were prepared for analysis by 
washing in PBS-T multiple times and fixing with 4 % paraformaldehyde as in 
previous protocols. 
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1.2.3.9 Electrophoresis of KP-08/pDNA complexes re-suspended in 
electroporation buffer 
 
A sample of polyplexes was prepared by mixing 40 µl of KP-08 with 25 µl of 
pDNA and incubating at room temperature for 15 minutes. This was done in 
duplicate and then one sample of polyplexes was diluted into 735 µl of 
electroporation buffer (thus bringing the polyplexes to the same final 
concentration as in an electroporation run) whilst the second sample of 
polyplexes was diluted into 335 µl of electroporation buffer. The rationale 
behind the second dilution was that DNA may not have been detectable 
during electrophoresis when a 20 µl sample of polyplexes was subsequently 
taken from the 800 µl electroporation sample for analysis on the agarose gel.  
 
20 µl of each sample was then separately mixed with 5 µl of loading solution 
and loaded into the wells of an 0.8 % agarose gel containing 0.5 µg/ml 
ethidium bromide.  
 
A sample of free DNA (2 µg) and a DNA ladder were also run on the agarose 
gel, with which the banding patterns of DNA in the hydrogel sample could be 
compared.  
 
Samples were run for 45 minutes at 95 V and the gel was then transferred to 
a UV light box for analysis. 
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1.2.3.10 Electrophoresis of CaP and CaP/KP-08 precipitates 
 
Agarose electrophoresis was undertaken on calcium phosphate precipitates 
formed either with or without KP-08 to compare the banding patterns of the 
DNA in each solution. Past electrophoresis results showed that KP-08 binds 
DNA and forms a distinct DNA band in the top of the lane of each well during 
electrophoresis and that there is no free DNA present in each lane. 
 
Calcium phosphate/KP-08 precipitates were formed as follows – 100 µl of KP-
08 was mixed with 5 µg of pDNA in a 1.5 ml eppendorf tube and incubated at 
room temperature for 10 minutes. 285 µl of ddH20 and 61 µl of 2 M CaCl2 was 
then added to the hydrogel bound DNA and the tube was tapped to mix the 
solution. Separately, 500 µl of 2X HBS was pipetted into a 15 ml centrifuge 
tube. The DNA/KP-08/CaCl2 solution was then added dropwise into the HBS 
solution, with gentle tapping on the side of the centrifuge tube after each drop. 
20 µl of the resulting precipitation was immediately mixed with 5 µl of loading 
solution (without tracking dye) and loaded into the agarose gel.  
 
Calcium phosphate (control) precipitates were formed in the same manner as 
above except no KP-08 was added to the DNA at the first step and 385 µl 
rather than 285 µl of ddH20 was used to bring the volume of the solution up to 
500 µl prior to mixing with the 2X HBS. As trial experiments at the beginning 
of the month had shown that incubating the precipitates prior to addition to 
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cells could affect transfection efficiency, two sets of CaP control precipitates 
were analysed through electrophoresis – one set that had been formed and 
then immediately loaded into the agarose gel, and another in which 
complexes were incubated for 30 minutes prior to being mixed with gel 
loading solution and being added to cells. 
 
Samples of free DNA and DNA mixed with calcium chloride (but not HBS in 
the second precipitate formation step) were also included in lanes of the gel 
along with a DNA ladder. 
 
1.2.3.11 Transfection of KP-08/Calcium Phosphate precipitates 
 
Precipitates were formed between KP-08-bound-pDNA and calcium 
phosphate, firstly by mixing 100 µl of KP-08 (10 mg/ml stock) with 5 µg of 
pDNA in an 1.5 ml eppendorf tube and incubating at room temperature for 10 
minutes. 61 µl of 2 M CaCl2 and ddH20 to a final volume of 500 µl were then 
added into the KP-08 solution and gently tapped before being added 
dropwise into 500 µl of 2X HBS (a HEPES buffered solution containing 1.5 
mM dibasic sodium phosphate) in a 15 ml centrifuge tube. The side of the 
tube was gently finger tapped after the addition of each drop. 100 µl of the 
precipitate was then diluted into a final volume of 2 ml of fully supplemented 
advanced DMEM media and then added onto cells (HaCaT cells pre-seeded 
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on the day before transfection onto 18 x 18 mm glass coverslips in 35 mm 
Petri dishes at a density of 5 x 105 cells/slide). 
 
The complexes were incubated with the cells for 20 hours at 37ºC (media 
change performed with fully supplemented RPMI 1640 the following morning) 
after which time the transfection solutions were aspirated off cells and 
replaced with 2 ml of fully supplemented advanced DMEM. The cells were 
then grown for a further 24 hours before being washed, fixed and washed 
again for analysis. Control treatments of CaP with pDNA (no KP-08) and 
pDNA alone were also run simultaneously.  
 
1.2.3.12 Particle Sizing of KP-08/pDNA/CaP complexes 
 
KP-08/pDNA/CaP complexes were formed and incubated for either 0 or 30 
minutes to determined whether the particles grew in size over time. 
 
KP-08/Calcium phosphate precipitates were formed by mixing 100 µl of KP-
08 with 5 µg of pDNA in a 1.5 ml eppendorf tube and incubating at room 
temperature for 10 minutes. 61 µl of 2 M CaCl2 and 340 µl ddH20 were then 
added into the KP-08 solution and gently tapped before being added 
dropwise into 500 µl of 2X HBS (a HEPES buffered solution containing 1.5 
mM dibasic sodium phosphate) in a 15 ml centrifuge tube. The side of the 
tube was gently finger tapped after the addition of each drop.  
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Standard calcium phosphate precipiates were formed as above except KP-08 
was omitted from the solution and 385 µl of ddH20 rather than 285 µl of ddH20 
was used when forming precipitates.  
 
Particle size analysis was carried out on dynamic light scattering particle 
sizing equipment (Brookhaven Instruments) by Dr Nicholas Crowther of AGT 
Sciences Ltd. The particle sizing instrument used photon correlation 
spectroscopy to generate values for particle diameters in each sample (nm). 
Samples were run for 30 minutes and results were generated using 
ZetaPALS particle sizing software version 3.48.  
 
1.2.3.13 Transfection of KP-08/pDNA/CaP complexes prepared with and 
without an incubation period 
 
Previous particle sizing experiments had highlighted how KP-08/pDNA/CaP 
complexes grew in size over time so it was decided that complexes formed 
either with or without an incubation period should be compared in a 
transfection experiment. 
 
NIH 3T3 cells cultured in fully supplemented advanced DMEM culture media 
were seeded out onto glass coverslips at a density of 5 x 104 cells per 
coverslip and grown overnight before transfection. Cell culture media was 
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replaced two hours prior to transfection with fresh media, which was then 
replaced with the appropriate transfection solution at the start of transfection. 
Transfection solutions were prepared as follows: 
 
KP-08/Calcium phosphate precipitates – 100 µl of KP-08 was mixed with 5 µg 
of pDNA in a 1.5 ml eppendorf tube and incubated at room temperature for 10 
minutes. 61 µl of 2 M CaCl2 and 340 µl ddH20 were then added into the KP-
08 solution and gently tapped before being added dropwise into 500 µl of 2X 
HBS (a HEPES buffered solution containing 1.5 mM dibasic sodium 
phosphate) in a 15 ml centrifuge tube. The side of the tube was gently finger 
tapped after the addition of each drop. 200 µl of the precipitate was then 
either immediately diluted into a final volume of 2 ml of fully supplemented 
advanced DMEM media and then added onto cells. Alternatively, precipitates 
were incubated at room temperature for 30 minutes before being diluted into 
cell culture media and being added to cells. 
 
Standard calcium phosphate precipitates – formed as above except KP-08 
was omitted from the solution and 385 µl of ddH20 rather than 285 µl of ddH20 
was used when forming precipitates. Complexes were added to cells either 
immediately or after 30 minutes of incubation. 
 
The complexes were incubated with the cells for 20 hours, after which time 
the transfection solutions were aspirated off cells and replaced with 2 ml of 
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fully supplemented advanced DMEM. The cells were then grown for a further 
24 hours before being washed, fixed and washed again for analysis. 
1.2.3.14 Nebulised delivery of KP-08/pDNA/CaP precipitates to cells 
 
NIH 3T3 cells were grown to confluence and then split 1:2 for transfection the 
following day. KP-08/CaP precipitates were prepared for transfection as 
follows:  
 
KP-08/Calcium phosphate precipitates – 100 µl of KP-08 was mixed with 5 µg 
of pDNA in a 1.5 ml eppendorf tube and incubated at room temperature for 10 
minutes. 61 µl of 2 M CaCl2 and 340 µl ddH20 were then added into the KP-
08 solution and gently tapped before being added dropwise into 500 µl of 2X 
HBS (a HEPES buffered solution containing 1.5 mM dibasic sodium 
phosphate) in a 15 ml centrifuge tube. The side of the tube was gently finger 
tapped after the addition of each drop. The 1 ml of precipitate prepared was 
then added to the well at the top of the nebuliser, which was sealed to the 
neck of the culture flask with parafilm to maximise the amount of mist entering 
the flask. When the nebuliser (Aeroneb go® nebuliser, Aerogen, Ireland) was 
connected to the mains supply the formulation immediately formed a mist, 
which filled the culture flask. After a few minutes when all mist had been 
produced by the nebuliser the top was screwed back onto the culture flask 
and the flask was laid down in the flow hood for 5 minutes to allow the mist to 
settle on the cells. This procedure was performed in duplicate with or without 
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8 ml of fully supplemented advanced DMEM  present in the culture flask at 
the point of exposure to the nebulised formation. In the latter scenario, cells 
were exposed to the mist for 5 minutes (incubated at room temperature) 
before the addition of 8 ml of media. Cells were then returned for overnight 
incubation at 37ºC. 
 
Standard CaP precipitates were formed in the same way (except KP-08 was 
omitted during precipitate formation) and nebulised as a control treatment. In 
the control, cells were exposed to the mist in the presence of 8 ml of culture 
media. 
 
After 24 hours flasks of cells were then trypsinised using 8 ml of trypsin-EDTA 
and then centrifuged to obtain a cell pellet. Supernatant was discarded off the 
cells and the pellet was re-suspended in 4 ml of fully supplemented advanced 
DMEM cell culture medium. 500 µl of the re-suspended cells was then 
seeded out onto 18 x 18 mm glass coverslips placed inside 35 mm Petri 
dishes containing 2 ml of media. Cells were grown for a further 2 hours before 
being washed, fixed and mounted for analysis. 
 
1.2.3.15 Optimiaztion of KP-08/pDNA/CaP complexes for transfection 
 
NIH 3T3 cells cultured in fully supplemented advanced DMEM media were 
seeded out onto glass coverslips at a density of 2.5 x 104 cells per coverslip 
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and grown in 35 mm Petri dishes overnight at 37º before transfection. When 
the cells were ready for transfection overnight growth media was aspirated off 
cells and replaced with the appropriate transfection solution. Transfection 
solutions were made up to investigate three parameters that may affect the 
efficiency of complex formation and thus transfection: 
 
1) The time for which precipitate was incubated for prior to being added to 
the cells 
2) The time for which KP-08/DNA was incubated with CaCl2 for before the 
KP-08/DNA/CaCl2 solution was added dropwise into a 2 X HBS 
solution. 
3) The incubation period of KP-08 with DNA prior to the addition of CaCl2 
to the polyplexes. 
 
All transfection solutions were made up with 5 μg of pDNA and 100 μl of KP-
08. A media change (2 ml fully supplemented advanced DMEM) was 
performed on all cells 1 hour prior to the onset of the transfection solutions.  
 
To investigate parameter 1, a 1 ml transfection solution was made up by 
mixing DNA with KP-08 and incubating the polyplexes for 10 minutes at room 
temperature. 285 μl of dH20 and 61 μl of 2 M CaC12 was then added to 
complexes and the solution was mixed by tapping the side of the eppendorf 
tube in which complexes were formed. The 500 μl of KP-08/DNA/CaCl2 
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solution was then added dropwise into 500 μl of 2 X HBS. The resulting 
precipitate was then incubated at room temperature for as long as necessary 
and added to cells either immediately after formation, 10 minutes or 40 
minutes after formation. In each case 200 μl of the transfection solution was 
pipetted dropwise into each Petri dish. 
 
To investigate parameter 2, KP-08/DNA were mixed and incubated at room 
temperature for ten minutes. 285 μl of dH20 and 61 μl of 2 M CaC12 was then 
added to complexes and the CaC12 was incubated with the polyplexes for 
either 0, 5 or 20 minutes before the KP-08/DNA/CaP solution was added 
dropwise into 2 X HBS. Once the two solutions had been mixed, 200 μl of 
each transfection solution was immediately pipetted into the appropriate Petri 
dish by dropwise addition. 
 
To investigate parameter 3, KP-08 and DNA were mixed and incubated at 
room temperature for either 0, 5 or 20 minutes before dH20 and CaCl2 were 
added into the polyplex solution. After the CaCl2 had been added, the KP-
08/DNA/CaCl2 solution was immediately added dropwise into 500 μl of 2 X 
HBS and once the two solutions had been mixed, 200 μl of each transfection 
solution was immediately pipetted into the appropriate Petri dish by dropwise 
addition. 
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A control treatment of standard CaP precipitates was also made up. 5 μg of 
pDNA, 385 μl of dH20 and 61 μl of 2 M CaCl2 were mixed together and 
immediately added dropwise into 500 μl of 2 X HBS. 200 μl of the resulting 
precipitate was then added to cells. 
 
All cells were grown at 37ºC in the presence of the respective transfection 
solution for 24 hours. After 24 hours a media change was performed using 2 
ml fully supplemented advanced DMEM media and cells were grown for a 
further 24 hours at 37ºC. 
 
All growth media was then aspirated off cells, which were washed for 10 
seconds at room temperature with PBS, fixed for 30 minutes at room 
temperature with 4 % paraformaldehyde and washed a further time for 10 
seconds at room temperature, again with PBS.  
 
1.2.3.16 Particle Sizing of Nebulised KP-08/pDNA/CaP precipitates 
 
1 ml of transfection solution was made up as in transfection experiments – 5 
μg of pDNA and 100 μl of 2 % KP-08 were mixed together and immediately 
mixed with 285 μl of dH20 and 61 μl of 2 M CaCl2. The KP-08/DNA/CaP 
solution was then added dropwise into 500 μl of 2 X HBS and immediately 
nebulised. The nebuliser outlet was sealed to the neck of a 20 ml sample tube 
using parafilm and the nebulised mist was collected into 4 ml of dH20. The 
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solution of dH20 containing nebulised formulation was then taken for particle 
sizing. 
Particle size analysis was carried out on dynamic light scattering particle 
sizing equipment (Brookhaven Instruments). The particle sizing instrument 
used photon correlation spectroscopy to generate values for particle 
diameters in each sample (nm). Samples were run for 30 minutes and results 
were generated using ZetaPALS particle sizing software version 3.48.  
 
1.2.3.17 Filtration of Nebulised KP-08/pDNA/CaP precipitates prior to 
transfection 
 
NIH 3T3 cells cultured in fully supplemented advanced DMEM media were 
seeded out onto glass coverslips at a density of 2.5 x 104 cells per coverslip 
and grown in 35 mm Petri dishes overnight at 37º before transfection. When 
the cells were ready for transfection overnight growth media was aspirated off 
cells and replaced with the appropriate transfection solution.  
 
A Transfection solution was made up as in previous experiments - 100 µl of 
KP-08 was mixed with 5 µg of pDNA in a 1.5 ml eppendorf tube and 285 µl 
ddH20 and then 61 µl of 2 M CaCl2 were immediately added to the polyplex 
solution. The KP-08/DNA/CaCl2 solution was then immediately pipetted 
dropwise into 500 µl of 2X HBS (a HEPES buffered solution containing 1.5 
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mM dibasic sodium phosphate) in a 15 ml centrifuge tube. The side of the 
tube was gently finger tapped after the addition of each drop.   
 
200 μl of the transfection solution was pipetted into cells in one Petri-dish 
containing 2 ml of fully supplemented advanced DMEM. The remaining 800 μl 
of the same solution was then quickly filter sterilised though a 450 nm filter 
and then 200 μl of the filtered transfection solution was then pipetted onto 
cells in a different Petri dish. 
 
This enabled a direct comparison to be made between filtered and non-
filtered transfection solutions. 
 
1.2.3.18 Evaluating the use of a different nebuliser 
 
NIH 3T3 cells were grown to confluence in T-75 culture flasks and then split 
1:2 for transfection the following day. The hydrogel stock used was 2 % KP-
08 (30/6/08) and had a pH adjusted to 2.75 with acetic acid. 
 
3 flasks of cells were transfected: 
1. Side Stream Nebuliser – A transfection solution was made up as 
follows: 100 μl of KP-08 was mixed with 10 μg of pDNA and then 285 
μl of dH20 and 61 μl 2 M CaCl2 were immediately added. The 
DNA/hydrogel/CaCl2 solution was then added dropwise into 500 μl 2 X 
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HBS. The 1 ml of transfection solution was then nebulised into a flask 
of cells containing 8 ml of advanced DMEM. The neck of the culture 
flask was sealed to the outlet on the nebuliser using parafilm during 
nebulisation. 
2. Transfection solution made up as in 1. but the solution was nebulised 
using the E-flow nebuliser.  
3. Transfection solution made up as in 1. but the solution was pipetted 
dropwise into a flask of cells rather than being nebulised. 
 
After nebulisation flasks were left in a horizontal position for five minutes to 
allow the mist time to settle on the media. Culture flasks were then returned to 
the incubator for incubation at 37ºC for 24 hours. 
 
At the end of the transfection period transfection media was aspirated off cells 
and cells were then trypsinised using 8 ml of trypsin-EDTA and then 
centrifuged to obtain a cell pellet. After the supernatant had been discarded 
the cell pellet was re-suspended in 4 ml of fully supplemented advanced 
DMEM cell culture medium. 500 µl of the cell suspension was then seeded 
out onto 18 x 18 mm glass coverslips placed inside 35 mm Petri dishes. Cells 
were given 15 minutes to allow attachment to the coverslips and then 2 ml of 
media was added to each well.  
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Cells were grown for a further 2 hours at 37 ºC before being washed, fixed 
and mounted for analysis. 
 
1.2.3.19 Agarose electrophoresis to detect pDNA in the nebulised 
solution 
 
An 0.8 % agarose gel containing 0.5 μg/ml ethidium bromide was made up 
using electrophoresis grade agarose (Invitrogen) and 1 X TAE buffer 
(Invitrogen).  
 
Samples for analysis were made up as follows: 
 
Naked DNA: 50 μg of pDNA was mixed with 950 μl of dH20 and nebulised 
with the E-flow. The neck of the nebuliser was sealed to a 20 ml specimen 
bottle containing 500 μl dH20. As much of the mist was recovered into the 
water as possible by swilling the collection tube and then the 500 μl was 
divided into two; one half of which was filtered through a 0.45 micron filter. 
 
A normal transfection solution was made up by adding 200 μl KP-08 (31/7/08) 
to 50 μl of pDNA and adding 190 μl water. 61 μl of 2 M CaCl2 was then added 
dropwise into 500 μl 2 X HBS. The resulting precipitate was nebulised in the 
E-flow and collected in 500 μl dH20. Half of the solution was passed through a 
0.45 micron filter.  
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20 μl of each of the four solutions was taken and mixed with 5 μl of loading 
buffer prior to loading into wells on the gel. A DNA ladder and a sample of 
free DNA were also included in separate lanes as reference samples. 
 
1.2.4 Examining the properties of POVAL Nanoparticles for 
gene delivery 
 
1.2.4.1 Examining stability of POVAL/pDNA complexes through 
electrophoresis 
 
Polyplexes were formed by mixing 2.12 µg of pDNA with 25 µl of a 10 mg/ml 
POVAL stock in 1.5 ml eppendorf tubes and incubating at room temperature 
for 10 minutes to produce sample a). 25 µl of sample a) was then pipetted 
into a new eppendorf and was diluted with 25 µl of sterile PBS to prepare 
sample b). 25 µl of sample b) was then pipetted into a new eppendorf and, 
after dilution with a further 25 µl of sterile PBS, formed sample c). 25 µl of 
sample c) was then pipetted into a new eppendorf and, after dilution with a 
further 25 µl of sterile PBS, formed sample d). In all cases, samples were 
incubated at room temperature for 10 minutes after being diluted with PBS 
before the next dilution was performed.  
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The procedure was then repeated after another set of POVAL/pDNA 
polyplexes had been synthesised. However, all dilutions took place in Opti-
MEM cull culture media to yield samples e) to h). 
 
Diluting samples in this way meant the following amounts of DNA were 
loaded into the gel after the 25 µl of the final samples had been supplemented 
with 5µl loading solution; 
 
a) 0.88 µg – samples A and E (lanes 4 and 8 respectively) 
b) 0.44 µg – samples B and F (lanes 5 and 9 respectively) 
c) 0.22 µg – samples C and G (lanes 6 and 10 respectively) 
d) 0.11 µg – samples D and H (lanes 7 and 11 respectively) 
 
Samples of free DNA and a DNA ladder (Bioline Hyperladder I) were also run 
on the gel and prepared as outlined in 2.2.9, in which electrophoresis 
parameters are also described.  
 
1.2.4.2 Evaluating POVAL nanoparticles during transfection  
 
NIH 3T3 cells were cultured as outlined in 2.2.1 and were seeded at a density 
of 5 x 104 cells per coverslip on the day preceding transfection as described 
in 2.2.10.  
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POVAL polyplexes were prepared by mixing 2.12 µg pDNA with 25 µl of 10 
mg/ml POVAL and incubating at room temperature for 15 minutes. Polyplexes 
were synthesised in duplicate and transfected over a period or either 5 or 24 
hours. In the case of the 5 hour transfection solution, the final volume of the 
solution was adjusted to 2 ml with Opti-MEM media. For the 24 hour 
transfection solution, Opti-MEM was added to the polyplexes to a final volume 
of 1.9 ml and then 100 µl NCS was added to the solution prior to addition to 
cells. 
 
Negative naked DNA controls were included using 2µg DNA suspended in 
either TE buffer or ddH20. Positive Lipofectin
® controls were also included 
forming lipoplexes according to manufacturers instructions with 2µg pDNA 
suspended in either TE buffer or ddH20. 
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1.2.5 Miscellaneous transfection-related experiments 
 
1.2.5.1 Transfection of HAE primary cells with POVAL/CaP precipitates 
Primary HAE cells purchased from Lonza were maintained in BEBM cell 
culture media and grown at 37ºC in a 5 % CO2 atmosphere. Prior to 
transfection cells were split from the culture flasks using trypsin-EDTA and 
seeded out onto 18 x 18 mm class coverslips placed inside 35 mm Petri 
dishes at a density of 2.5 x 104 cells per coverslip. As the primary cells were 
slow growing it was necessary to grow the cells for a further week prior to 
transfection, with a media change (2 ml fresh BEBM) performed after three 
days. 
 
On the day of transfection growth media was aspirated off cultures and 
replaced with 2 ml of transfection solution. Transfection solutions were made 
up as follows. 
 
1. Calcium phosphate control – 10 μg of pDNA was mixed with 390 μl 
dH20 and then 61 μl of 2 M CaCl2. The DNA/CaCl2 solution was then 
added dropwise into 500 μl of 2 X HBS and incubated at room 
temperature for 5 minutes. 50 μl of the resulting CaP precipitate was 
then added to the cells instead of 200 μl as is typically done during 
transfection, because at the latter volume the precipitate had proven 
toxic to cells in a preliminary transfection experiment. 
 69 
2. POVAL/CaP precipitate – transfection solution formed as in 1) except 
200 μl of 0.5 % POVAL (1/8/08) was added to the pDNA before the 
addition of 190 μl of dH20. 50 μl of the final solution was pipetted onto 
cells. 
3. Lipofectin control – A Lipofectin control was made up according to 
manufacturers instructions, as in previous experiments. Cells were 
exposed to transfection solution containing a total of 2 μg of pDNA in 
the lipoplex solution. 
4. Lipofectin/POVAL transfection solution. Transfection solution was 
made up as in 3 except 40 μl of 0.5 % POVAL (1/8/08) was mixed with 
DNA during the first step. 
5. POVAL transfection solution -  40 μl of 0.5 % POVAL (1/8/08) was 
mixed with 2 μg of DNA and incubated for 15 minutes prior to addition 
to cells. 
6. Naked DNA control – cells were exposed to 2 μg of DNA diluted to a 
final volume of 2 ml in BEBM cell culture media. 
 
The final volume of all cultures was adjusted to 2 ml using BEBM cell culture 
media and cells were transfected over a 24 hour period. After this time a 
media change was performed (2 ml fresh BEBM) and cells were grown for a 
further 24 hours to permit the expression of any GFP. 
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Growth media was then aspirated off cells, which were washed, fixed and 
mounted for analysis as in previous protocols.  
 
1.2.5.2 Electrophoresis of PEI/pDNA complexes 
 
In order to verify the efficacy of the plasmid pDNA and confirm the cell types 
used were transfectable an additional control technique was evaluated – PEI, 
polymer-based, transfection.  
 
Firstly, polymer and pDNA were mixed at various nitrogen: phosphate ratios 
to determine the minimum amount needed to bind all pDNA in a given 
sample. 0.0675 g of PEI (Acros Organics, approx MW 60,000, 50 % wt a.q. 
solution, branched) was diluted into 75 ml of sterile filtered (0.2 micron) ddH20 
to yield a stock of 10 mM PEI. The solution was stirred with a spatula for 5 
minutes until all PEI had dissolved. The pH was adjusted to 7.3 using HCl and 
the solution was then sterile filtered through a 0.2 micron filter and stored at 
4ºC until use. 
 
Various quantities of the stock solution were then taken and mixed with pDNA 
to yield final ratio‟s of 16:1, 32:1, 64:1 and 128:1 N:P (5.2 ug of pDNA in each 
sample). 
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pDNA and PEI were separately diluted into 50 ul of 150 mM NaCl and 
vortexed on a low speed for ten seconds. The solution were incubated at 
room temperature for ten minutes before being mixed together and being 
subjected to another 10 min incubation period. 20 μl of the resulting solution 
was mixed with 5 μl of loading buffer and loaded into a 0.8 % agarose gel 
containing 0.5 μg/ml ethidium bromide. Samples were ran in a Bio Rad 
electrophoresis tank for 1 hour at 80 V, after which time the gel was 
photographed under UV light box. 
 
1.2.5.3 Transfection of PEI-pDNA polyplexes 
 
HaCaT cells were seeded out onto glass coverslips at a starting cell density 
of 5 x 104 cells per well and grown overnight in fully supplemented RPMI 
media.  
 
The following morning transfection solutions were prepared as in the 2.3.21 
experiment at a ratio of 4:1 (5ul of PEI stock solution diluted into 50 ul of 150 
mM NaCl solution, and 20.5 ul pDNA separately diluted into 50 ul of 150 mM 
NaCl solution and incubated for ten minutes prior to mixing). 
 
200 ul was then pipetted onto the cells, which were incubated for 5 hours at 
37 degrees C in serum-free media.. After that time a 2 ml media change was 
performed with fully supplemented RPMI and the cells were grown overnight. 
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The following morning another media change was performed and the cells 
were grown for a final 24 hours before being washed, fixed and mounted for 
analysis. 
 
1.2.5.4 Examining complex formation through particle size analysis 
 
A sample of free DNA was prepared by diluting DNA to a concentration of 
62.5 µg/ml to a total volume of 5 ml. Samples of POVAL nanoparticles were 
prepared by diluting the stock solution 1:10 into either PBS or distilled water 
to yield working concentrations of 1 mg/ml. Samples of polyplexes were 
synthesised by mixing 675 µl of hydrogel nanoparticles from the working 
stock (diluted in PBS) straight with 4.32 ml of pDNA (62.5 µg/ml) in TE buffer. 
A second sample of polyplexes were prepared by diluting the nanoparticles 
and DNA prior to mixing by  mixing 96 µl of pDNA (62.5 µg/ml) into 300 µl of 
Opti-MEM and incubating at room temperature for 45 minutes. 
Simultaneously, 15 µl of 1 mg/ml POVAL (diluted in PBS) was diluted into 300 
µl of Opti-MEM and left for incubation at room temperature for 30 minutes. 
Both pDNA and hydrogel solutions were then combined, mixed gently, and 
incubated for a further 10 minutes at room temperature before a further 5.4 ml 
of Opti-MEM was added. 5 ml of the final sample was taken for particle size 
analysis using dynamic light scattering particle sizing equipment (Brookhaven 
Instruments). The particle sizing instrument used photon correlation 
spectroscopy to generate values for particle diameters in each sample (nm). 
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Samples were run for between 24 and 52 minutes and results were generated 
using ZetaPALS particle sizing software version 3.48.  
 
1.2.5.5 Conductimetric titrations 
 
The lack of nanoparticle uptake observed in transfection experiments could 
possibly have been attributable to a charge effect. Thus it was decided that  
conductimetric titrations would be performed, first of PD2000 against calf 
thymus DNA, and then with KP-08 against calf thymus DNA, to determine 
whether KP-08 and DNA were being mixed at appropriate amounts during 
polyplex formation for transfection experiments. 
 
PD2000 vs calf thymus DNA 
 
25 ml of a 1 % (w/w) PD2000 was made up using distilled water and pipetted 
into a beaker. A solution of 1 % (w/w) calf thymus DNA was similarly prepared 
with distilled water and was titrated into the beaker at 0.5 ml intervals, with 
conductivity readings recorded using a handheld conductivity meter (Hanna 
Instruments). 
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KP-08 vs calf thymus DNA 
 
25 ml of a 0.5 % KP-08 formulation was pipetted into a beaker. A solution of 1 
% (w/w) calf thymus DNA was similarly prepared with distilled water and was 
titrated into the beaker at 0.25 ml intervals, with conductivity readings 
recorded using a handheld conductivity meter (Hanna Instruments). 
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1.3. Results 
1.3.1 Examining the properties of KP-08 nanoparticles for 
gene delivery 
 
1.3.1.1 Gel mobility shift assay to determine the optimal KP-08/pDNA 
binding ratio  
 
Figure 3 shows at low ratios of KP-08:DNA, such as 6:1 or 8:1, there is an 
insufficient amount of KP-08 present to bind pDNA in a 0.53 µg DNA sample. 
As the amount of KP-08 used in polyplex formation increases (moving 
towards the right across Figure 3) less and less DNA appears in the lanes of 
each lane as it has been bound to the hydrogel and remains in the wells at 
the top of each lane.  
 
 
Fig. 3 – agarose gel mobility shift assay of KP-08(18/7/07)/pDNA complexes. Complexes 
formed at hydrogel to pDNA ratios in indicated at the top of each lane per μg of pDNA . Total 
                                           6         8       12      16       24      31       48      63      94     126    189 
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amount of pDNA in each lane was 0.53  μg. The two samples in the far left hand lanes are a 
DNA ladder and a sample of free pDNA (0.53 μg) 
 
 
At a ratio of 48:1 there appears to be little, if any, pDNA in the lane. However, 
it is only at a ratio of 189:1 that a thick DNA band, indicating complete 
polyplex formation (i.e. no residiual, unbound DNA in the lane), is really 
visible in the well at the top of a lane. 
 
It was decided that for future experiments polyplexes would be formed at a 
ratio of 200:1 µg KP-08:  µg DNA as a surplus of KP-08 would at least ensure 
that all DNA in a given sample was bound to the hydrogel. Preliminary 
experiments had shown KP-08 to have no adverse affects on cell viability, so 
an excess of KP-08 had not proven to be detrimental to cell cultures. 
 
1.3.1.2 Determining minimum charge needed to bind pDNA and complex 
stability through agarose electrophoresis  
 
Figure 4 a) shows that with the 1/0.01 nanoparticles (least positively 
charged), complexes between KP-08 and DNA formed, as indicated by the 
band of DNA in the well at the top of lane 5. When the polyplexes were 
diluted into Opti-MEM (lanes 6 – 12), however, DNA release was observed in 
all samples, regardless of the pH of the media. As a result, the 1/.01 solution 
is of no use for transfection as any DNA that is coupled to the hydrogel would 
be released upon dilution into buffered media (with an identical pH to that in 
lane 6), which is part of the transfection procedure. 
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Similarly, Figure 4 b) shows that with the 1/0.02 KP-08, complexes initially 
formed between the KP-08 and DNA (lane 4) but that DNA was immediately 
released upon dilution into Opti-MEM media (lanes 5 – 11). Again, DNA 
dissociation was observed at all pH‟s, including at physiological pH (lane 5), 
indicating that 1/.02 complexes would also be of no use for transfection 
studies. 
 
However, Figure 4 b) shows with the 1/.03 KP-08 that DNA dissociation was 
not apparent when KP-08/pDNA complexes were diluted into Opti-MEM 
suggesting that nanoparticles with this PD2000 concentration were able to 
bind DNA (lane 12) and maintain the interaction when diluted into media 
(lanes 13-19). 
 
There does appear to be a smeared pattern in some of the lanes in both 
Figures 4 b) and c), but this may have been produced by the contrast settings 
on the picture. What is clear in Fig. 4 b) is that bands of DNA that are visible 
in the 1/.02 solutions, level with the arrow to the left of the image, are not 
present in the 1/.03 solutions, as DNA has remained bound to the 1.03 KP-08 
(represented by faint bands in the wells at the top of lanes 13-19), rather than 
dissociating and appearing as free pDNA further down the lanes as is the 
case with the 1/.02 solution (lanes 5-11 Fig. 4 b).  
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                                                                              1/.01 
 
 
 
 
Fig. 4 a) – electrophoresis of KP-08 (1/.01)/pDNA complexes diluted into Opti-MEM media of 
differing pH. A DNA ladder was included in lane 4. In lane 5 was a sample of KP-08/pDNA 
which had not been diluted into Opti-MEM (to check complexes had formed before dilution 
into Opti-MEM). Lane numbers and the pH of the buffer used in sample preparation for each 
lane are indicated above the image. Lanes 1-3 were blank. 
 
Figure 4 c) shows that with the 1/.03 and 1/.04 solutions DNA bound to the 
KP-08 (lanes 4 and 12 respectively) and that in both cases, the resulting 
complexes that formed remained stable when diluted into Opti-MEM. For both 
the 1/.03 solution (lane 5-11) and the 1/.04 solution (lanes 13-19) DNA bands 
are visible in the wells at the top of each lane as the DNA was bound in a 
complex with a net positive charge that did not migrate towards the positive 
electrode as unattached, negatively charged DNA would have done. 
 
   Lane:                     1       2       3      4        5      6        7     8         9      10    11     12 
 pH:                                                                                         7.65      7      6.42     6.15      5.51   5.05    4.04 
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                                                       1/.02                                              1/.03 
 
 
 
 
Fig. 4 b) – electrophoresis of KP-08 (1/.02 and 1/.03)/pDNA complexes diluted into Opti-MEM 
media of differing pH. A DNA ladder was included in lane 3. In lane 4 was a sample of KP-08 
(1/0.02)/pDNA which had not been diluted into Opti-MEM (to check complexes had formed 
before dilution into Opti-MEM). Lane numbers and the pH of the buffer used in sample 
preparation for each lane are indicated above the image. Lanes 1-2 and 20 (at each end of 
the gel) were blank. 
 
In summary, these results suggest that somewhere between the 1/.02 and 
1/.03 solutions is a critical level of PD2000 required to bind all DNA in a 
sample and maintain the interaction when diluted into cell culture media. With 
the KP-08 formulation at least, if the concentration of PD2000 is below this 
level, any DNA bound to the hydrogel will simply dissociate from the hydrogel 
upon dilution into cell culture media. It was decided that in order to ensure 
complete binding, a 0.05 % concentration of PD2000 would be used thereon 
in. 
Lane:   1     2    3     4     5    6     7    8    9   10    11   12   13  14   15   16  17   18  19   20 
 pH:                                      7.65   7    6.42  6.15 5.5 15.05  4.04           7.65  7    6.42  6.15 5.51  5.05 4.04 
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                                                       1/.04                                              1/.05 
 
 
 
 
Fig. 4 c) – electrophoresis of KP-08 (1/.04 and 1/.05)/pDNA complexes diluted into Opti-MEM 
media of differing pH. A DNA ladder was included in lane 3. In lane 4 was a sample of KP-
08/pDNA which had not been diluted into Opti-MEM (to check complexes had formed before 
dilution into Opti-MEM). Lane numbers and the pH of the buffer used in sample preparation 
for each lane are indicated above the image. Lanes 1-2 and 20 (at each end of the gel) were 
blank. 
 
 
1.3.1.3 Evaluating KP-08 nanoparticles during transfection  
 
At the point of analysis following transfection, GFP expression was noted in 
cells transfected with the hydrogel. Fig. 5 below shows two GFP-expressing 
3T3 cells, which were transfected over a period of 5 hours in the absence of 
   Lane: 1      2     3      4     5      6      7     8      9     10   11   12    13    14    15   16    17   18    19   20 
 pH:                                          7.65    7     6.42   6.15   5.51  5.05   4.04           7.65    7     6.42   6.15  5.51  5.05   4.04 
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serum and chloroquine. In total, only a small number of NIH 3T3 cells were 
transfected, with 5 counted in total. In comparison, Lipofectin® controls have 
demonstrated much higher levels of transfection with over 2,000 GFP-
expressing NIH 3T3 cells counted in previous experiments. 
 
However, no GFP-expressing cells were observed in any of the other 
hydrogel treatments, regardless of whether transfection had taken place over 
5 or 24 hours or had been performed in the presence or absence of 
chloroquine. 
 
 
Fig. 5 – GFP expression detected in NIH 3T3 cells exposed to KP-08/pDNA complexes. Cells 
transfected over 5 hours in the absence of serum and chloroquine. 
 
As no GFP expression was detected in cells exposed to naked DNA over 
either 5 or 24 hours it would appear that the observed GFP expression in Fig. 
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5 resulted from DNA carried into the cells as part of the KP-08 vector rather 
than in a free form.  
 
1.3.1.4 Examining DNA release from KP-08 nanoparticles at different pH  
 
Figure 6 shows that complexes of KP-08 and pDNA had successfully formed 
(a sample of complexes which were not diluted into Opti-MEM media was 
included in lane 13) and that when the complexes were subsequently diluted 
into Opti-MEM media of differing pH, the KP-08 maintained an interaction with 
pDNA in all cases except when complexes had been diluted into media of pH 
5.15 (lane 10). The result in lane 10 show that, at pH 5.15, pDNA was 
released from the KP-08, a result not witnessed at the higher or lower pH‟s 
tested in this experiment.  
 
 
 
 
Figure 6 – electrophoresis of KP-08/pDNA complexes diluted into Opti-MEM media of 
differing pH. In lane 3 is a DNA ladder and in lane 4 is a sample of free pDNA (equivalent 
amount to that in lanes 5-13). In lane 13 was a sample of KP-08/pDNA which had not been 
   Lane:         1       2       3       4       5       6       7       8       9       10     11     12     13     14     15   
 pH:                                             7.8   7.15   6.54   5.93   5.57   5.15    4.68   4.01 
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diluted into Opti-MEM (to check complex formation was still occurring prior to dilution into 
media). Lane numbers and the pH of the buffer used in sample preparation for each lane are 
indicated above the image. Lanes 1-2 and 14-15 (at each end of the gel) were blank. 
 
The fact that DNA appeared to be released at pH 5.15 suggested there was 
the possibility DNA may be released from the hydrogel in the endosome 
(which has a pH of ~5) if complexes were internalised by endocytosis.  
 
1.3.1.5 Transfection of KP-08/Lipofectin® chimeric complexes  
 
The result in figure 7 suggested that all of the plasmid DNA in the sample had 
been bound to the hydrogel as there was no evidence of free, unattached 
DNA in lane 4. Thus, it can be assumed that any GFP expression that may be 
detected in cells exposed to chimeric nanoparticles in the subsequent 
experiment was produced by transfecting with DNA simultaneously bound to 
both KP-08 and Lipofectin®. 
 
Successful transfection was noted in cells exposed to the chimeric complexes 
– 134 GFP expressing cells were counted in total (see Fig. 8), compared to 0 
GFP expressing cells in the KP-08/pDNA treatment. 1,360 GFP expressing 
cells were counted in the Lipofectin® control but none were counted in the 
cells exposed to naked DNA which had not been bound to any vector. 
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Figure 7. – electrophoresis of chimeric complexes. In lane 2 is a DNA ladder, lane 3 is naked 
pDNA whilst in lane 4 is a sample of chimeric nanoparticles. 
 
 
Figure 8. – 3T3 cells transfected with chimeric KP-08/Lipofectin® nanoparticles. Transfection 
was performed over 6 hours in the absence of serum, with a total of 350 GFP expressing 
cells counted in total. x 50 magnification. 
 
        Lane:     1       2       3       4      
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If it is assumed that all pDNA in the sample was simultaneously bound to both 
KP-08 and Lipofectin® during transfection then the results from this 
experiment suggest that pDNA is able to dissociate from the hydrogel inside 
the cell – otherwise GFP expression would not have been noted in cells 
transfected with the chimeric nanoparticles. A hypothetical mechanism for 
cellular entry for the chimeric nanoparticles could be membrane fusion with 
the plasma membrane, as opposed to endocytosis (thus circumventing the 
problem of escape from the endosome for any complexes that are 
endocytosed), which would lead to localisation of the KP-08/pDNA complex in 
the cytoplasm. If the pDNA was then able to dissociate from the KP-08 and 
traffic itself to the nucleus then GFP expression could subsequently be 
induced. 
 
During liposomal based transfections, opinion is divided as to how lipoplexes 
are internalised into cells. Authors such as Li & Huang (2000) and Leng and 
Mixson (2005) state lipoplexes are endocytosed whilst Kamata et al. (1994), 
Ourlin et al. (1997) and Mozafari & Omri (2007) suggest membrane fusion is 
the route of entry. It may be that a combination of the two processes permits 
internalisation of lipoplexes. Evidence from this project has shown liposomal 
based reagents to be effectively internalised into the cell.  
 
However, the results from this experiment, like the majority of those 
previously recorded during the project, showed no GFP expression in cells 
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transfected with KP-08/pDNA complexes. It was postulated that this may 
because of a lack of nanoparticle uptake. 
 
1.3.1.6 Using rhodamine-labelled pDNA to detect successful vector 
internalisation  
 
Cells analysed immediately after transfection 
 
There was evidence of rhodamine-labelled plasmid in cells exposed to KP-08 
nanoparticles, chimeric nanoparticles and in the Lipofectin® control. However, 
there was no evidence of rhodamine in free DNA control. 
 
However, there were large differences between the amount of rhodamine-
labelled plasmid detected in cells exposed to the different transfection 
vectors. In cells exposed to Lipofectin®, which has repeatedly been shown to 
successfully transfect cells in previous experiments, there was a widespread 
abundance of tiny red speckles distributed all across the coverslip (see Fig. 9 
a). Such fluorescent patterns were absent from the free DNA control, in which 
no speckles of rhodamine were noted. 
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Figure 9 a) – cells exposed to Lipofectin
®
, analysed immediately after the 5 hour transfection 
period. Evidence of rhodamine-labelled plasmid around and inside the nucleus (indicated by 
arrow) was noted. The number of rhodamine speckles noted was extremely large (not all 
visible on the photo), with rhodamine distributed across all of the coverslip. The point of 
analysis was too early for GFP detection, however. Images were taken using ACT-2U 
software as in the previous experiment, through x 100 magnification.  
 
In cells exposed to the chimeric nanoparticles (synthesised by mixing 
polyplexes of KP-08 and DNA with Lipofectin®), there was widespread 
evidence of internalised plasmid (see Fig. 9 b), although not to the same 
extent as in the Lipofectin® control. Lastly, in the cells exposed to KP-08 
nanoparticles there was evidence of rhodamine labelled plasmid in cells (only 
faintly visible to the left of the arrow in Fig. 9 c), but it was very sparse and 
abundance of rhodamine was largely reduced in comparison to the chimeric 
particles and Lipofectin® control. 
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Figure 9 b) – Cells exposed to chimeric nanoparticles, analysed immediately after the 5 hour 
transfection period. Evidence of rhodamine-labelled plasmid inside cells was noted although 
in the cells captured in this image the plasmid had not entered the nucleus by the point of 
analysis. 
 
 
Figure 9 c) – cells exposed to KP-08/pDNA nanoparticles, analysed immediately after the 6 
hour transfection period. One speckle of rhodamine is present towards the bottom right hand 
corner of the image, and although was not located in the nucleus, appeared to have localised 
in the cell cytoplasm. The number of rhodamine speckles noted on this coverslip overall was 
very low, however. 
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Cells analysed 43 hours post-transfection: 
 
In the cells analysed 43 hours post transfection the same patterns of 
rhodamine fluorescence were noted compared to when cells were analysed 
immediately after transfection – the greatest distribution of rhodamine was in 
the Lipofectin® control with the least amount of plasmid in the cells exposed to 
KP-08. No rhodamine was detected in cells exposed to free DNA, whilst a 
good amount of rhodamine was detected in the chimeric treatment, although 
not to the same levels as in the Lipofectin® control. 
 
As cells had been grown for longer prior to analysis the cell density was 
increased compared to those analysed straight after transfection (greater 
number of DAPI-stained nuclei visible).  
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Figure 9 d) – cells exposed to Lipofectin
®
, analysed 42 hours post transfection. Delaying the 
onset of analysis provided transfected cells sufficient time to express the GFP protein, as 
indicated in the above photo. There are around ten visible rhodamine dots on the photo 
indicating the presence of internalised plasmid. In all cases, internalised rhodamine is located 
in close proximity to the cell nuclei, but only in two of the above cells has GFP been 
expressed. It may have been that one of the two transfected cells was stably transfected (i.e. 
the plasmid became integrated into the host cell chromosome) and that the second 
transfected cell is a ‘clone’ daughter cell. Alternatively, both cells may have been separately 
transfected. To determine whether the cells had been stably or transiently transfected, 
antibiotic selection of the culture would be required as the plasmid encodes neomycin 
resistance to successfully transfected cells. 
 
However, lengthening the time prior to analysis meant GFP expressing cells 
were now visible at the point of analysis in both the Lipofectin® (see Fig. 9 d) 
and chimeric treatments (Figure 9 e). There were approximately 400 GFP 
expressing cells counted in cells exposed to Lipofectin® compared to 200 with 
the chimeric nanoparticles. However, no GFP expression  was detected in 
cells exposed to free DNA or KP-08 nanoparticles, despite the fact 
rhodamine-labelled plasmid was located inside cells transfected with KP-08 
nanoparticles (albeit in very small numbers). 
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Figure 9 e) – cells exposed to chimeric nanoparticles, analysed 42 hours post transfection. 
Delaying the onset of analysis provided transfected cells sufficient time to express the GFP 
protein, as indicated in the above photo. GFP expression is noted in both the nucleus – 
where the DAPI and GFP images overlap and in the cell cytoplasm, where the green area of 
fluorescence marks the boundaries of the cell. There is evidence of rhodamine in the 
cytoplasm of the transfected cell, as indicated by the red dot, but also in the cell in the top 
right of the photo. In the latter case, however, transfection has not been successful as no 
GFP expression was observed. 
 
 
Figure 9 f) – cells exposed to KP-08 nanoparticles. Viewing cells exposed to KP-08 
nanoparticles through DAPI and rhodamine filters showed that cells were present on the 
coverslip and that there was rare evidence of rhodamine speckles on the slide, indicating 
internalisation of the polyplex. However, no GFP expression was detected in any cells on the 
slide. The large difference in the number of rhodamine speckles present on this slide 
compared to the Lipofectin and chimeric nanoparticles suggested that the vast majority of 
KP-08 was not being internalised into cells because of inefficient endocytosis. 
 
1.3.1.7 Investigating primary cells as an alternative target cell type  
 
Evidence of rhodamine uptake and GFP expression was only noted in cells 
transfected with Lipofectin, not in cells exposed to KP-08 nanoparticles or in 
the naked DNA control (regardless of whether DNA had been labelled or not). 
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Fig. 10a  – articular chondrocytes transfected with Lipofectin
®
 complexed to rhodamine-
labelled plasmid DNA. GFP expression was also noted in the same cells, although levels of 
GFP expression were much higher when transfections were performed using unlabelled 
pDNA. 
 
Chondrocytes were shown to be successfully transfected by the Lipofectin® 
complexed with unlabelled DNA with around 700 GFP-expressing cells 
counted in total (see Figure 10b below) 
 
 
Fig. 10b) – GFP expression noted in articular chondrocytes transfected with Lipofectin
®
 and 
unlabelled plasmid. 
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1.3.1.8 Electroporation of HaCaT cells with KP-08/pDNA complexes 
 
Evidence of GFP expression in the naked DNA control (see Fig. 11a) below) 
confirmed the efficacy of the plasmid DNA stock used during the experiment 
and that electroporation parameters were appropriate for transfection. 
Secondly, a lack of GFP expression in the KP-08 control (in which no DNA 
was added) suggested that KP-08 alone could not achieve transfection. 
 
 
Fig 11a) – HaCaT cells electroporated with naked DNA, analysed 24 hours post-
electroporation. x 50 magnification 
 
In the experimental treatment in which cells had been electroporated in the 
presence of KP-08/pDNA complexes, GFP expression was noted, indicating 
successful transfection in at least 250 cells. This finding, assuming that all 
DNA was bound to the hydrogel during the electroporation procedure, 
suggested that the KP-08 formulation did not prevent DNA release into the 
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cytoplasm and thus did not prevent GFP expression from taking place if 
complexes were located into the cytoplasm. 
 
 
Fig 11b) – HaCaT cells electroporated with KP-08/pDNA complexes, analysed 24 hours post 
transfection. x 50 magnification 
 
1.3.1.9 Electrophoresis of KP-08/pDNA complexes re-suspended in 
electroporation buffer 
 
Figure 12 suggested that KP-08 had successfully bound DNA into polyplexes 
(lane 6) which remained intact when diluted into electroporation buffer at the 
two concentrations selected (lanes 7 and 8). In lanes 7 and 8 a band of DNA 
was faintly visible in the well at the top of each lane, however, there was no 
evidence of unbound DNA migrating down the lane towards the positive 
electrode as in lane 5 (control lane). 
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Thus, these results suggested that during the previous electroporation 
experiment, the DNA that was successfully uptaken into the cells during the 
electroporation procedure was likely to have been bound to KP-08 at the point 
of entry into cells. 
 
 
Fig 12 – Electrophoresis of the following samples: lanes 1-3: blank, 4: DNA ladder, 5: sample 
of free DNA, 6: sample of KP-08/DNA complexes undiluted into buffer, 7: KP-08/DNA 
complexes diluted into electroporation buffer (400 µl final volume), 8: KP-08/DNA complexes 
diluted into electroporation buffer (800 µl final volume). All other lanes are blank. 
 
1.3.1.10 Electrophoresis of CaP and CaP/KP-08 precipitates 
 
The results showed that DNA present in standard calcium phosphate 
precipitates migrated down the lane (lanes 4 and 5) in the same manner as 
free DNA (control lane 3). When DNA was mixed with calcium chloride but not 
mixed with HBS thereafter (as would be the case in precipitate formation) the 
result remained identical, as the DNA fragment migrated the same distance 
down lane 7. 
 
Lane: 1         2        3         4        5         6        7        8         9        10      11     12       13       14      15 
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Fig. 13  – Agarose electrophoresis of KP-08/CaP and CaP precipitates. Lanes 1 and 8-15 are 
blank. In lane 2 is a DNA ladder whilst lane 3 contains a sample of free DNA. Lanes 4 and 5 
are samples of CaP formed with or without a pre-incubation period. Lane 6 is a sample of KP-
08/CaP and lane 7 is a sample of DNA mixed with calcium chloride but which was not taken 
through mixing with sodium phosphate in the second precipitate formation step. 
 
In contrast, when KP-08 is added to the DNA during precipitate formation the 
majority of DNA remains in the well at the top of lane (lane 6). A band of 
nicked DNA is present around a third of the way down lane 6, which is also 
present in the other lanes, however, the thick band of plasmid DNA present in 
lanes 3,4,5 and 7 is not observable, suggesting that the DNA is bound to the 
hydrogel. The fact that transfection has been achieved with such precipitates 
would suggest that the hydrogel-gel-bound DNA is still precipitating with 
calcium phosphate thereafter, just that it fails to produce the same banding 
pattern on an agarose gel. 
 
1.3.1.11 Transfection of KP-08/Calcium Phosphate precipitates 
 
When cells were observed at the point of analysis, GFP expression was 
noted in cells exposed to the hydrogel/CaP precipiates (see Figs. 14 a-c)) 
     Lane       1      2      3       4       5      6       7       8      9      10     11    12     13      14    15    
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with around two hundred GFP expressing cells counted in total. This was a 
notable increase from previous experiments when either hydrogel 
nanoparticles alone or hydrogel/liposome „chimeric‟ vectors had been used.  
 
GFP expression was also noted in the positive CaP control, in which around 
500 GFP-expressing cells were counted. However, there was no evidence of 
transfection in the naked DNA negative control.  
 
It was interesting to note that GFP expression had been detected in 3T3 cells 
because HaCaT cells exposed to the same precipitates (both the KP-08/CaP 
precipitates or standard CaP precipitates) had previously displayed no 
evidence of GFP expression. 
 
 
Fig 14a) -  NIH 3T3 cells transfected with KP-08/CaP precipitates, a few hundred GFP 
expressing cells were counted in total 
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Although there were a greater amount of GFP-expressing cells in the CaP 
control, suggesting that the presence of the hydrogel may, in some way, 
hinder gene expression, it may be that adding hydrogel to the formulation 
confers some other benefit, such as the ability to nebulise the formulation. 
 
 
 Fig 14b) - NIH 3T3 cells transfected with KP-08/CaP precipitates, a few hundred GFP 
expressing cells were counted in total 
 
The results of this experiment (see Figs. 14a) and b)) show a marked 
improvement in the transfection efficiency of the hydrogel, albeit in the 
presence of CaP. It appears that mixing hydrogel-bound DNA with calcium 
chloride and sodium phosphate does not prevent precipitation, and thus the 
complexes are still endocytosed in the same manner as standard CaP 
precipitates. It must be acknowledged, however, that an assumption has been 
made during the experiment – that all of the DNA present in the KP-08/CaP 
precipitates was bound to the KP-08 prior to the addition of the calcium 
phosphate. Previous electrophoresis results would suggest that this is the 
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case, however, if DNA and KP-08 were not associated with one another then 
the gene expression observed could have been a result of transfection 
achieved with residual DNA forming precipitates with CaP. 
1.3.3.12 Particle Sizing of KP-08/pDNA/CaP complexes 
 
Particle sizing measurements showed both in the presence and absence of 
KP-08, calcium phosphate-pDNA precipitates grew in size over time. When 
KP-08 was present, the complexes were larger (started off around 1 micron in 
diameter in the presence of KP-08 as opposed to around 850 µm without KP-
08) and they grew at a faster rate over time.  
 
In conclusion it appears that because the KP-08/CaP precipitates start off 
much larger than CaP precipitates, they can only be incubated for a short 
time before addition to cells. Prolonging the incubation period of such 
complexes for too long means the precipitate grows excessively, and may be 
too large to be endocytosed by cells. Thus, in future experiments Kp-08/CaP 
precipitates will be added immediately to cells in an attempt to maximise cell 
uptake. 
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1.3.3.13 Transfection of KP-08/pDNA/CaP complexes prepared with and 
without an incubation period 
 
With standard CaP-pDNA precipitates formed in the absence of KP-08, only 
98 GFP-expressing cells were counted when complexes were immediately 
added to cells, however, after a 30 min incubation period with precipitates, 
this number was increased to 486. 
 
In contrast, however, when KP-08 was present in the precipitate the opposite 
result was noted, with 915-GFP expressing cells counter when the 
precipitates were immediately added to cells, with this figure dropping to only 
49 in a 30 min incubation step was added before the complexes were added 
to cells. Together with the particle sizing experiments, these results indicate 
that because the complexes grow in size over time there is a small window of 
opportunity for them to become exposed to cells before they grow in size too 
big to be uptake by the target cells. When KP-08 is excluded in the control 
precipitates, transfection efficiency increases in time over time, although it is 
expected to only increase up to a point and is worth noting that such 
complexes start at a smaller size to those containing KP-08 anyway. Studies 
in the literature have revealed that taking absorbance readings of precipitates 
at an optical density of 320 nm can reveal whether precipitates are likely to be 
efficient during transfection. A reading of 0.2/0.3 is preferable in the 
absence/presence of DNA. When transfection solutions were formed and 
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analysed 1 hour post preparation the standard CaP precipitates produced a 
reading of 0.117, or 0.187 if the precipitates had been incubated prior to 
addition to cells. When KP-08 is added to the solution the starting reading is 
larger, although increases in size over time are also noted. 
1.3.3.14 Nebulised delivery of KP-08/pDNA/CaP precipitates to cells 
 
On the coverslip of cells exposed to the nebulised KP-08/DNA/CaP 
precipitate (transfected in the presence of media) a total of 977 GFP-
expressing cells were counted (see Figure 15), however, no GFP expression 
was observed in the control treatment in which cells had been exposed to a 
nebulised formulation of the standard CaP precipitate or when transfection of 
the KP-08/DNA/CaP precipitate was performed with media omitted from the 
flask. 
 
 
Fig 15): NIH 3T3 cells transfected with the nebulised KP-08/DNA/CaP 
precipitate 
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Thus, it would appear that including cell culture media in the flask during 
transfection improves the rate of transfection as a drastic increase in GFP 
expression was observed compared to when media was omitted from the 
flask. 
Additionally, the absence of GFP expression in the control suggests that the 
presence of the hydrogel in the precipitate confers some advantage over the 
standard CaP precipitate as a transfection solution. 
 
1.3.3.15 Optimiaztion of KP-08/pDNA/CaP complexes for transfection 
 
Parameter 1 
 
The aim of investigating parameter 1 was to ascertain whether incubating the 
KP-08/CaP precipitates prior to addition to cells could increase levels of gene 
expression. Although 249 GFP-expression cells were counted when the 
precipitate was immediately added to cells (see Fig. 16) below), levels of 
gene expression dropped when the incubation period of the precipitate was 
extended, with 104 GFP expressing cells visible after 5 minutes incubation, 
and only 50 noted after 20 minutes of incubation. 
 
Particle sizing measurements taken last month showed that the KP-08/CaP 
precipitates grow over time and thus the reduced levels of gene expression 
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observed after an extended incubation period are probably attributable to the 
precipitates growing to a size when they become too big to be endocytosed.  
 
Figure 16 - KP-08/CaP precipitate formed and added straight to cells without any prior 
incubation at room temperature. 
 
Parameter 2 
 
The aim of investigating parameter 2 was to determine whether there was an 
optimal time with which KP-08/DNA polyplexes should be incubated with 
CaCl2 for prior to dropwise addition into the HEPES buffered solution 
containing the sodium phosphate (2X HBS). 
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Results showed that if the KP-08/DNA/CaCl2 solution was immediately added 
onto the 2 X HBS that 302 GFP-expressing cells were observed (see Fig 17) 
below). However, if the polyplexes were incubated with CaCl2 for 5 or 20 
minutes prior to addition into the HBS then the number of GFP expressing 
cells observed decreased to 213 and 144 respectively.  
 
 
Figure 17) - KP-08/DNA/CaCl2 solution immediately added to 2 X HBS during precipitate 
formation, with no incubation period of CaCl2 with the polyplexes 
Again, this highlighted the benefit of making up the precipitate as quickly as 
possible, shortening incubation periods as much as possible in between each 
step of the precipitate forming procedure. 
Parameter 3 
 
The aim of investigating parameter 3 was to determine whether there was an 
optimal time for which KP-08 and DNA should be incubated together for prior 
to the addition of CaCl2. 
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When KP-08 and DNA were mixed and CaCl2 was added immediately 
afterwards, a total of 485 GFP-expressing cells were counted. However, if the 
polyplexes were incubated for either 5 or 20 minutes before CaCl2 was added 
then the number of transfected cells observed decreased to 268 and 123 
respectively. 
 
 
Figure 18) CaCl2 immediately added to cells after KP-08 and DNA initially mixed together 
during the polyplex formation step 
 
Finally, GFP expression was noted in the standard CaP control, with a total of 
188 GFP-expressing cells counted. However, this transfection efficiency 
remained lower than the most efficient transfection achieved with the 
hydrogel. 
 
In summary, these results highlighted several parameters during the 
precipitate formation procedure that influence transfection efficiency, 
presumably by optimising precipitate formation.  The highest rates of 
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transfection were achieved when the precipitate formation procedure was 
performed without incubation periods in between each step.  
 
1.3.3.16 Particle Sizing of Nebulised KP-08/pDNA/CaP precipitates 
After the nebulised solution had been collected it was transferred into a 
cuvette for particle sizing measurements. However, the solution was not 
producing a clear signal and it was thus necessary to filter the solution 
through a 0.45 micron filter and take particle sizing measurements from the 
filtered solution. This acted to remove any background from the solution and 
showed that the transfection particles were approximately 190 nm in diameter 
prior to nebulisation but that after nebulisation particle size increased to 
approximately 300 nm. Particle sizing measurements were taken every two 
minutes for twenty minutes, which showed that the particles grew by no more 
than 10 % of their original size by the end of the sampling period. 
 
Past particle sizing experiments sized KP-08/DNA/CaP precipitates at  
around 1 micron at the start of the sampling period and 1.7 microns at the 
end. This was larger than DNA/CaP precipitates which were around 850 nm 
to start with and grew to around 1.3 microns by the end of the sampling 
period. These findings tied in with spectophotometric readings of DNA CaP 
precipitates from earlier in the project, which indicated that precipitates grew 
in size over time. 
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As the solutions had been filtered the results were not going to show particles 
as large as before. However, even after filtration it was possible to ascertain 
that they had grown in size during nebulisation.  
 
1.3.3.17 Filtration of Nebulised KP-08/pDNA/CaP precipitates prior to 
transfection 
 
At the point of analysis 42 GFP expressing cells were counted in the non-
filtered treatment.  
 
 
Fig. 19 – GFP-expressing cell observed after exposure to a  non-filtered transfection solution. 
 
However, 0 GFP expressing cells were counted in the filtered treatment, 
suggesting that it is the KP-08/DNA/CaP precipitates sized above 450 nm that 
are responsible for achieving transfection. 
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1.3.3.18 Evaluating the use of a different nebuliser 
No GFP-expression was noted in the cells exposed to the precipitate 
nebulised with the Sidestream nebuliser, however, 6 GFP-expressing cells 
were noted when the E-flow nebuliser had been used. Strangely, no GFP 
expression was noted in the treatment in which the transfection solution had 
been pipetted dropwise into the culture flask, even though such treatments 
have demonstrated transfection in the past. It may have been that 
transfection did take place in this solution at a low rate and that transfected 
cells were not identified during analysis.  
 
 
Fig. 20 – GFP expression in NIH 3T3 cells exposed to transfection solution nebulised with the 
E-flow nebuliser. 
 
The fact that only 6 GFP-expressing cells were counted following E-flow 
nebulisation suggested that transfection remained very inefficient as there 
were several hundred thousand viable cells present on each coverslip at the 
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point of analysis. It was decided that a new hydrogel solution would be 
formulated and nebulisation would be repeated with the E-flow nebuliser. 
 
1.3.3.19 Agarose electrophoresis to detect pDNA in the nebulised 
solution 
 
 
Fig 21: Agarose electrophoresis of the following samples: lanes 1-3 blank, lane 4 DNA 
ladder, lane 5 a sample of free DNA, lane 6 nebulised sample of free DNA, lane 7 nebulised 
sample of free DNA filtered, lane 8 KP-08/CaP precipitate nebulised and collected, lane 9 
KP-08/CaP precipitate nebulised, collected and filter sterilised. Lanes 10-15 blank. 
 
The results showed that in the hydrogel solution (non-filtered) DNA was 
present in the well at the top of lane 8, suggesting that there was DNA coming 
through the nebuliser and that it remained bound in a complex with a net 
positive charge, which did not migrate towards the negative electrode. 
However, when the solution was filter sterilised little if any DNA was present 
in the well or lane in lane 9, suggesting that the DNA is bound to a complex 
larger than 0.45 microns.  
 
This has implications for transfection because it suggests that the DNA is 
being presented to cells during transfections and that the nebuliser isn‟t 
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blocked and preventing cells from being exposed to the transfection solution. 
The results also suggest that the majority, if not all of the DNA that is being 
presented to cells during nebulisations, is bound in a complex that is sized 
above 0.45 microns. The size of the complexes alone does not explain why 
transfection has proven inefficient because the standard calcium phosphate 
precipitates are similarly sized around a micron and still produce transfection. 
 
Finally, the results in figure 21 also show that when DNA was nebulised by 
itself (attached to no vector), none was detected in the collected samples 
(non-filtered, lane 6 or filtered, in lane 7), suggesting that a simple DNA 
solution cannot be nebulised. 
 
1.3.2 Examining the properties of POVAL Nanoparticles for     
gene delivery     
 
1.3.2.1 Examining the stability of POVAL/pDNA complexes through 
electrophoresis  
 
By forming polyplexes and performing serial dilutions in either PBS or Opti-
MEM it was possible to examine the stability of the POVAL-pDNA complexes 
when they were diluted down to low concentrations. Such stability at low 
concentrations was essential during transfection, when a 50 µl volume of 
polyplexes would be diluted into a final volume of 2 ml of cell culture media.  
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The results in Figure 22 show that polyplexes remained stable upon dilution 
into both PBS (lanes 4-7) and Opti-MEM media (Lanes 8-11) and that all DNA 
had remained bound to the hydrogel in each sample. In lanes 4-11 there was 
an absence of free, unbound DNA, which would have migrated as in lane 12 
(control lane of free DNA) 
 
   
Fig. 22 – electrophoresis of the following samples; 
Lane 1 – Blank 
Lane 2 – Blank 
Lane 3 - DNA molecular weight ladder 
Lane 4 – pDNA/hydrogel complex diluted in PBS after complex formation 
Lane 5 – two fold dilution of the sample loaded in lane 4 
Lane 6 – two fold dilution of the sample loaded in lane 5 
Lane 7 – two fold dilution of the sample loaded in lane 6 
Lane 8 - pDNA/hydrogel complex diluted in Opti-MEM media after complex formation 
Lane 9 – two fold dilution of the sample loaded in lane 8 
Lane 10 – two fold dilution of the sample loaded in lane 9 
Lane 11 – two fold dilution of the sample loaded in lane 10 
Lane 12 – naked pDNA (re-suspended in distilled water) 
Lane 13 – dye used to track the migration of fragments across the gel 
Lanes 14 and 15 – blank 
 
                     1      2      3      4      5      6      7      8      9     10    11    12    13    14    15 
         
 
 
 
 
 
 
 
4.7 kb → 
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The banding intensity varied between lanes because of the varying amounts 
of DNA in each lane – a consequence of the serial dilutions performed in 
sample preparation. 
 
As in the previous experiment it appeared that all of the DNA in the hydrogel 
samples had a decreased mobility on the agarose gel because of charge 
neutralisation of the phosphate backbone of the DNA and because the 
polyplexes had an increased molecular size (Akinc et al. 2005; Chen et al. 
2007; Pack et al. 1999). As the POVAL polyplexes were shown to be stable it 
was decided that a transfection attempt would be undertaken. 
 
1.3.2.2 Evaluating POVAL nanoparticles during transfection  
 
Although NIH 3T3 cells exposed to POVAL nanoparticles appeared healthy 
no GFP expression was detected regardless of whether transfection period 
had been 5 or 24 hours. However, in the Lipofectin® controls GFP expression 
was observed regardless of whether the DNA stock had been re-suspended 
in TE buffer (see Fig. 23a) or ddH20 (see Fig. 23b), confirming that the 
plasmid used was able to produce transfection if complexed with the right 
vector.  
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Fig. 23a) – NIH 3T3 cells transfected with Lipofectin
®
 complexed with pDNA re-suspended in 
TE buffer. GFP-expression was also noted in the Lipofectin
®
 control in which plasmid had 
been suspended in ddH20, however. Image taken on a Leitz Dialux 22 microscope through 
x50 magnification. 
 
 
Fig. 23b) – NIH 3T3 cells transfected with Lipofectin
®
 complexed with pDNA re-suspended in 
TE buffer. GFP-expression was also noted in the Lipofectin
®
 control in which plasmid had 
been suspended in ddH20, however. Image taken on a Leitz Dialux 22 microscope through 
x50 magnification. 
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The lack of GFP expression observed in the cells exposed to POVAL 
nanoparticles could have been observed for several reasons. Firstly, the 
nanoparticles may not have been uptaken by cells during transfection. 
Secondly, if nanoparticles had been uptaken, GFP release may have been 
hindered if the DNA was too tightly bound to the hydrogel and unable to 
escape in order for transcription factors to access the DNA (Bertshinger et al. 
2006). Alternatively, the polyplex may have been internalised into the cell but 
was unable to escape the endosomal compartment and was thus degraded, 
which was the fate of the PVA nanoparticles administered to cells by Wittmar 
et al. (2005). 
1.3.3 Miscellaneous transfection-related experiments 
 
1.3.3.1 Transfection of HAE primary cells with POVAL/CaP precipitates 
 
No transfection was noted when POVAL alone was used for transfection or 
when naked DNA had been incubated with cells. Surprisingly, no 
transfection was observed using the calcium phosphate precipitate, even 
though this same formulation has been shown to repeatedly transfect cell 
lines in vitro (but not HaCaTs). Similarly, no transfection was observed in 
cells exposed to the POVAL/CaP precipitate, although the results from the 
Lipofectin treatments confirmed that the primary cells were infact 
transfectable; with 114 GFP expressing cells noted in the Lipofectin control  
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(fig 24a) and 26 GFP expressing cells noted in the POVAL/Lipofectin 
treatment (fig 24b). 
 
 
Fig 24a): Primary HAE cells transfected with Lipofectin. A total of 114 GFP-expressing 
cells were counted in total. 
 
 
Fig 24b): Primary HAE cells transfected with 0.5 % POVAL/Lipofectin. A total of 26 GFP-
expressing cells were counted in total. 
 
Although the total number of GFP expressing cells counted in these 
treatments remains much smaller than that in cell lines, it is worth noting 
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that the overall density in these treatments was much smaller because the 
primary cells were slow growing. 
 
1.3.3.2 Electrophoresis of PEI/pDNA complexes 
 
Results showed that at low N:P ratios (1:1 or 2:1) there is an unsufficient 
amount of nitrogen present in the sample to bind all pDNA. However, at a 
ratio of 4:1 or greater DNA was clearly visible as a band in the top of the 
well in each lane, suggesting complex formation has taken place. There 
was no migration of free pDNA down the lane, suggesting the polymer has 
bound all pDNA. 
 
1.3.3.3 Transfection of PEI-pDNA polyplexes 
 
330 GFP-expressing cells were noted in the PEI polyplex treatment at the 
point of analysis. This was in contrast to the naked DNA control, in which 
no GFP expression was noted. These results show PEI to be an easy 
method to follow and it proved fairly effective, without any attempt at 
optimization. 
 
1.3.3.4 Examining complex formation through particle size analysis 
 
Particle sizing of POVAL polyplexes was undertaken to gain an idea of the 
size of the POVAL nanoparticles and plasmid DNA to determine whether 
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they would be of a small enough size to be endocytosed either alone, or 
when combined, during transfection. It has generally been suggested that 
smaller nanoparticles are more desirable for gene delivery as they are 
more effectively endocytosed (Pack et al. 1999) and Guy et al. (1995) 
reported efficient endocytosis of complexes sized under 150 nm in 
diameter. Nevertheless, authors such as Gan et al. (2005), Kaul & Amiji 
(2005), Yi et al. (2006) and Zhao et al. (2006), amongst others, have 
produced nanoparticles with size ranges in excess of this and have still 
reported successful transfection. For example, Kaul & Amiji (2005) 
synthesised gelatin nanoparticles within a 100-500 nm range, with an 
average particle diameter of 200 nm. 
 
Particle sizing results showed that POVAL nanoparticles had a diameter of 
37 nm when diluted in water, but that particle diameter increased to 76.3 
nm when nanoparticles were diluted into PBS, most probably due to 
flocculation in the phosphate containing buffer. As pDNA alone was sized 
at 118.9 nm the diameter of the polyplexes may have been expected to be 
approximately the sum of the POVAL and DNA values. However, this was 
not the case as the diameter of the polyplexes was 114.7 nm, a reduction 
on the diameter of pDNA alone.  
 
Sample Particle Diameter (nm) 
 pDNA alone 118.9 
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Hydrogel nanoparticles diluted in 
water 
37 
Hydrogel nanoparticles diluted in 
PBS 
76.3 
Hydrogel nanoparticles complexed 
straight with pDNA (polyplexes) 
without prior dilution 
114.7 
Hydrogel/pDNA polyplexes with prior 
dilution in media 
17894.4 
Table 6 – particle sizes of hydrogel nanoparticles, pDNA and hydrogel/pDNA complexes 
 
The reduced value of 114.7 nm is probably a mean value of two discrete 
particle populations in the sample if DNA and POVAL had not formed 
complexes, skewed towards the value for free DNA as there was a greater 
proportion of pDNA in the sample relative to the hydrogel nanoparticles. In 
order to investigate this matter further agarose electrophoresis was 
subsequently performed on a sample of polyplexes. 
 
When the POVAL and DNA were diluted in Opti-MEM prior to mixing and 
the resulting polyplexes were sized a particle diameter of 17894.4 nm was 
recorded. This would appear not be a true value, and rather could be 
attributable to background in the sample instead as the POVAL and DNA 
were diluted down to such a low concentration in the Opti-MEM media. 
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1.3.3.5 Conductimetric titrations 
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Fig 25a) – Conductimetric titration of calf thymus DNA vs PD2000. The endpoint appeared 
to be reach after 1 ml of DNA had been added to the solution of PD2000 
 
Figure 25a) above shows that the endpoint of the experimental run 
appeared to be reached after 1 ml of DNA had been added to the solution 
of PD2000. As both the PD2000 and DNA solutions had been made up to 
identical concentrations (1% w/w), the results suggested that for every 1 
volume of DNA, 25 volumes of PD2000 were required to ensure the 
resulting complexes possessed a positive charge. It was decided that the 
procedure would be repeated except DNA would be titrated against KP-08 
rather than PD2000 alone. 
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KP-08 vs calf thymus DNA 
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Fig 25b) – Conductimetric titration of calf thymus DNA vs 0.5 % KP-08 formulation. The 
endpoint appeared to be reach after 3 ml of DNA had been added to the solution of KP-08. 
 
With reference to figure 25b), in terms of the relative amounts of PD2000 
(present in the KP-08 formulation) mixed together with calf thymus DNA at 
the end point – after 3 ml of DNA had been added - there was, on a weight 
by weight basis, 0.03 g of DNA mixed with 0.00625 g of PD2000. However, 
taking into account the fact that DNA has a much large molecular weight 
compared to PD2000 (1,000,000 compared to 3,000 for PD2000), in terms 
of a molar basis, one mole of DNA was mixed with 69.44 moles of PD2000 
at the titration endpoint. 
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In comparison, during transfection experiments, when polyplexes are 
formed, 40 µl of KP-08 is mixed with 25 µl of pDNA. In terms of a 
weight/weight ratio that involves mixing 400 µg of KP-08 with 2 µg of DNA. 
On a molar basis, that equates to mixing 3333 moles of PD2000 for every 1 
mole of DNA used during complex formation. As a result, this calculation 
suggests that the amount of PD2000 present in complex formation is in fact 
in surplus and that the lack of a positive charge is unlikely to be hampering 
uptake of the nanoparticles.  
 
Furthermore, these results - suggesting a net positive charge of the 
complex - confirm what the electrophoresis results have repeatedly showed 
previously – that PD2000 has neutralised the negative charge on the DNA 
and prevented movement towards the positive electrode. 
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2. Evaluating the use of cross-linked PVA 
nanoparticles for drug delivery 
 
2.1 Introduction 
 
The aim of the second part of the project was to determine whether cross-
linked PVA particles would be able to enhance drug delivery of budesonide to 
eukaryotic cells. Previous work within AGT Sciences Ltd (unpublished) 
showed Nanagel® (a cross-linked PVA nanoparticle) to improve the solubility 
of hard to dissolve drugs such as budesonide and tobramycin and previous 
transfection work conducted as part of this project revealed Nanagel® to be 
non-toxic to cell cultures when combined with pDNA. 
 
Asthma and chronic obstructive pulmonary disease (COPD) are common 
respiratory conditions characterized by episodic and reversible airway 
obstruction (Huynh et al. 2010). The worldwide prevalence of both diseases is 
increasing, with societal implications in terms of morbidity, mortality and costs 
(Thorsson & Geller, 2005).  
 
Inhaled corticosteroids (ICS) are considered the cornerstone of therapy for 
patients with asthma and reduce exacerbations in COPD (Thorsson & Geller, 
2005). Their use is justified by their efficacy as they are very effective in 
controlling symptoms, reducing exacerbations, improving the health status of 
patients and reducing asthma mortality (Barnes, 2006). The benefits of their 
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use outweigh the unwanted side effects, such as reduced growth velocity and 
decreases in bone mineralization (Allen et al. 2003). 
 
Five corticosteroids are available as inhaled formulations for the treatment of 
asthma in the UK: beclometasone dipropionate, fluticasone propionate, 
mometasone furoate, ciclesonide and budesonide (NICE 2008) and a range 
of inhalation devices have been developed as a means of targeting ICS to 
airways. Ultimately, the choice of drug and inhalation device varies from 
patient to patient and is determined on an individual basis, however, 
budesonide offers flexibility to clinicians as it is available in metered dose 
inhalers in both proprietary (Pulmicort®, AstraZeneca) and non-proprietary 
(Novalizer, Meda) formulations, dry powder inhalers (Pulmicort Turbohaler, 
AstraZeneca), hard capsule powder inhalers (Cyclocaps, APS) (Nice, 2008) 
and as a nebulisable solution, Pulmicort Respules® (Thorsson & Geller, 
2005).  
 
Despite their widespread use, research into corticosteroid delivery has 
continued as it is estimated that only 10 – 40 % of ICS are deposited in the 
lung, with the remainder swallowed and passed through the GI tract (Allen et 
al. 2003), wastage that is increased in pediatric patients (Huynh et al. 2010). 
As a consequence, any means of improving drug delivery would be desirable. 
Additionally, there is a need to improve drug dissolution, especially important 
in the case of budesonide as the drug has a low solubility in water of < 1 
mg/100 ml (Jacobs & Muller, 2002). 
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In view of the need for improved drug dissolution and enhanced drug delivery 
AGT Sciences Ltd, Bradford, have recently developed cross-linked poly(vinyl 
alcohol) based Nanagel® nanoparticles that have been shown to efficiently 
entrap budesonide and are fully nebulisable (D. Eagland, pers. comm). The 
purpose of this study was to demonstrate that the budesonide contained 
within the nanosuspension (BUDAS) was readily uptaken by cells in vitro and 
effective in suppressing the production of reactive oxygen species (ROS) 
during a stimulated respiratory burst. 
 
In previously described work cellular respiratory bursts have been produced 
and measured in vitro using stimulants including formyl-methionyl-leucyl-
phenylalanine (fMLP) (Braga et al, 2005, Dal Sasso et al. 2005, Pruett & 
Loftis, 1990) and phorbol-12-myristate-13-acetate (PMA) (Braga et al, 2005, 
Black et al, 1994, Elferink 1984, Tan & Berridge, 2000, Theron 1994) and 
measuring the reduction of cytochrome c (Black et al 1991, Bjorquist et al. 
1994, Pick & Mizel, 1981) MTT (Burdon et al. 1993, Pruett & Loftis, 1990), 
WST-1 (Tan & Berridge, 2000) or using luminol-amplified (Dal Sasso et al. 
2005) or lucigenin (Theron et al. 1994) chemiluminescence.  Typically 
neutrophils have been extensively used for such studies, but here we present 
an alternative but simple and inexpensive means of stimulating SOD-
inhibitable ROS production in HaCaTs, measurable by the turnover of WST-1. 
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HaCaTs are an ideal cell to study in an inflammatory model as they are 
deficient in the intracellular redox mediator, NAD. This interferes with their 
ability to use glycolysis as their main energy source and thus they circumvent 
the problem by consuming glutamine, which inadvertently leads to the 
accumulation of NADPH oxidase, the ROS products of which are used for 
energy (Benaventre & Jacobsen, 2008). The readily accessible supply of 
latent NOX allows the possibility of an enzyme being mobilized by the 
application of external stimuli.   
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2.2 Methods 
 
2.2.1 TNF-α/fMLP stimulation of HaCaTs 
  
TNFα in cojunction with fMLP was used in an attempt to stimulate an 
oxidative burst in HaCaT cells. 
 
HaCaT cells grown in RPMI media were seeded into tissue-culture-treated 
96-well plates at a concentration of 1 x 104 cells per well and grown overnight 
at 37ºC to permit cell attachment and spreading. Media totalling a volume of 
250 μl was added to each well for the duration of this period. The following 
morning overnight media was aspirated off cells which were rinsed with 200 μl 
HBSS which was then discarded. 
 
Cells were stressed with 150 μl solution per well for 45 minutes, primed with 
135 μl of 10 ng/ml TNF (the batch of TNF used had already been pre-
aliquotted in RPMI media in the lab and thus it was not possible to eliminate 
all traces of media from the solution. Subsequent dilutions were prepared in 
HBSS however) mixed with 10 % (v/v) WST-1. After that point 50 μl of FMLP 
was added, diluting down the FMLP to a final concentration of 10-6 M. 
Absorbance readings (450 nm) were taken every 15 minutes. 
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2.2.2 Comparison of media vs TNF-α as a stress mediator 
 
HaCaT cells grown in RPMI media were seeded into tissue-culture-treated 
96-well plates at a concentration of 1 x 104 cells per well and grown overnight 
at 37ºC to permit cell attachment and spreading. Media totalling a volume of 
250 μl was added to each well for the duration of this period. The following 
morning overnight media was aspirated off cells which were rinsed with 200 μl 
HBSS which was then discarded. 
 
Stressor solutions were made up as in the previous experiment, to a final 
volume of 150 μl per well. TNF (aliquotted in RPMI media) was diluted 1:10 in 
HBSS in the experimental treatment whilst in the controls RPMI media was 
diluted 1:10 (v/v) in HBSS (“diluted media”) or mixed straight with WST-1 
without any traces of RPMI present in the well (“control”). Readings were 
taken every 15 minutes. 
 
2.2.3 Cell Penetration studies 
 
Primary human airway epithelial cells (NHBE) cells (Lonza, UK) were grown 
at 37ºC in a 5 % CO2 atmosphere in BEGM
® cell culture media, 
supplemented with BulletKit® growth supplements, as recommended by the 
supplier. Cells were grown in ventilated T-75 culture flasks (Corning, UK), 
sub-cultured upon reaching 80 % confluence, and seeded into tissue-culture-
treated 12-well plates when required for experimental purposes. 
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NHBE cells were grown to confluence, growth media was aspirated off cells, 
which were rinsed with 1 ml of HBSS (Promocell, Germany) which was 
subsequently discarded. BUDAS and Pulmicort® were diluted to a final 
budesonide concentration of 0.5 µg/ml in BEGM media and 1 ml added to 
cells for either 1 or 24 hours, after which time drug-containing medium was 
aspirated off cells. Cells were rinsed with 1.5 ml HBSS (subsequently 
discarded) and then lysed by the addition of 1ml ddH20 with incubation at 4ºC 
overnight. Any remaining cells attached to the bottom of the culture flask were 
removed with a cell scraper and the cell lysate soution was extracted using 
solid phase extraction techniques. Samples were then analysed using HPLC 
by Dr Dinesh Nadarassan at the Institute of Pharmaceutical Innovation, 
Bradford. 
 
2.2.4 Cell Retention Studies 
 
NHBE cells were grown as previously described. Cells were seeded into 
tissue-culture-treated 12 well-plates and grown to confluence. All growth 
media was then aspirated off cells which were rinsed with 1 ml of HBSS 
which was subsequently discarded. BUDAS and Pulmicort® were diluted to a 
final budesonide concentration of 0.5 µg/ml and 1 ml added to cells for a 
period of 24 hours. After this time cells were either prepared for analysis, or 
washed, and in the latter case a media change was performed with 1 ml fresh 
BEGM for a further 23 hours incubation at 37ºC. When ready for analysis, 
growth media was aspirated off cells, which were rinsed with HBSS. 1 ml of 
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ddH20 was then used to lyse cells by incubation at 4ºC overnight. Any 
remaining cells attached to the bottom of the culture flask were removed with 
a cell scraper and the cell lysate soution was extracted using solid phase 
extraction techniques. Samples were then analysed using HPLC by Dr 
Dinesh Nadarassan at the Institute for Pharmaceutical Innovation, Bradford. 
 
2.2.5 Measuring background absorbance of MTT/WST-1 in the absence 
of cells 
 
The background turnover of MTT (Sigma-Aldrich, UK) and WST-1 (Roche, 
France) in media solutions was determined by diluting 5 mg/ml MTT 
(aliquotted in PBS, sterile filtered) or neat WST-1, 1:10 into either HBSS 
(Promocell, Germany) or RPMI 1640 (Lonza, UK) medium, the latter of which 
was pre-supplemented with HEPES and L-Glutamine and was further 
supplemented with 10 % (v/v) foetal calf serum (Promocell, Germany), 100 
U/ml penicillin-streptomycin (Sigma, UK) and 1 µg/ml amphotericin B (Sigma, 
UK) (fully supplemented RPMI), 
 
200 μl of each solution was loaded into 96-well plates and the resulting 
absorbance (450 nm for WST-1 or 595 nm for MTT) read at ten minute 
intervals on a MRX microplate reader (Dynex Technologies, UK). 
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2.2.6 Identifying the media component responsible for ROS production 
 
HaCaTs were maintained in fully supplemented RPMI 1640 medium, 
supplemented as described previously. Cultures were incubated at 37ºC with 
5 % CO2 in a humidified atmosphere, and grown to 80 % confluence in T-75 
tissue culture flasks, with sub-culturing taking place three times per week.  
 
When required for experimental purposes, HaCaTs were seeded into tissue-
culture-treated 96 well plates (Corning, UK) at a density of 1 x 104 cells per 
well and incubated overnight in a 100 µl volume of fully supplemented RPMI 
to permit cell attachment and spreading. The following morning overnight 
media was aspirated off cells, which were rinsed with 200 µl HBSS which was 
subsequently discarded. 
 
Media solutions were prepared by diluting 200 µl of either fully supplemented 
or unsupplemented RPMI or 20 µl foetal calf serum into a final volume of 2 ml 
HBSS. HBSS was used as a negative control. 20 µl of all these solutions was 
then discarded and replaced with 20 µl of WST-1 per treatment. 200 µl of 
each media solution containing WST-1 was then added to each well and the 
resulting absorbance read at 450 nm on a MRX microplate reader at hourly 
intervals. 
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2.2.7 SOD inclusion during cell stressing 
 
HaCaT cells were cultured as previously described until required for 
experimental use, upon which they were seeded into tissue-culture-treated 
96-well plates at a concentration of 2 x 104 cells per well and grown overnight 
at 37ºC in a 100 μl volume of fully supplemented RPMI to permit cell 
attachment and spreading.  
 
The following morning overnight media was aspirated off cells which were 
rinsed with 200 μl HBSS which was then discarded. Media solutions were 
prepared by diluting fully supplemented RPMI 1:10 in HBSS, alternatively a 
solution comprised of HBSS was used as a negative control.  WST-1 
(aliquotted neat) was added to each solution to a final concentration of 10 % 
(v/v) and 150 µl was added per well. Absorbance measurements were taken 
at 450 nm every 30 minutes for a total of four hours. 
 
2.2.8 Attenuation of OB after pre-treatment with corticosteroids 
 
HaCaT cells grown in RPMI media were seeded into tissue-culture-treated 
96-well plates at a concentration of 1 x 104 cells per well and grown overnight 
at 37ºC to permit cell attachment and spreading. Media totalling a volume of 
100 μl was added to each well for the duration of this period. The following 
morning overnight media was aspirated off cells which were rinsed with 200 μl 
HBSS which was then discarded. 
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50 μl of BUDAS was diluted into a final volume of 5 ml fully supplemented 
RPMI to yield a working concentration that contained 5 µg/ml budesonside. 
200 μl of the resulting solution was then loaded into wells (200 µl RPMI added 
into control wells). Pulmicort®, at an equivalent budesonide concentration, 
was used as control. Cells were grown in the presence of the BUDAS for 24 
hours at 37ºC, after which time the BUDAS solution was aspirated off cells, 
which were rinsed with 250 μl HBSS that was subsequently discarded.  
 
Cells were then stressed with 10 % fully supplemented RPMI medium diluted 
in HBSS (10 % WST-1) (as in the positive control in which cells were exposed 
to the same solution but had not been pre-incubated with either BUDAS or 
Pulmicort® previously) with a total volume of 150 μl per well. A negative 
control (HBSS and WST-1) was made up to indicate the background level of 
absorbance on the HaCaT cells. Absorbance readings (450 nm) were taken 
at an end point of 2 hours. 
 
2.2.9 Stressing Cells in the presence of corticosteroids 
 
HaCaT cells grown in RPMI media were seeded into tissue-culture-treated 
96-well plates at a concentration of 2 x 104 cells per well and grown overnight 
at 37ºC to permit cell attachment and spreading. Media totalling a volume of 
100 µl was added to each well for the duration of this period. The following 
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morning overnight media was aspirated off cells, which were rinsed with 
HBSS (wash solution subsequently discarded). 
 
BUDAS was diluted into 10 % RPMI (diluted in HBSS) and WST-1 was added 
to a final concentration of 10 % (v/v). The final concentration of budesonide in 
this BUDAS solution was 5 µg/ml, with 200 µl loaded per well. Pulmicort® was 
prepared in the same manner and used for comparison at an identical 
concentration. Positive controls of 10 % RPMI containing WST-1 and 
negative controls of WST-1 diluted in HBSS were also prepared. Cells were 
stressed for six hours, with absorbance readings recorded every hour (A450 
nm). 
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2.3 Results 
 
2.3.1 TNF-α/fMLP stimulation of HaCaTs 
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Figure 26 – stimulation of HaCaTs with stressors (in media.) Error bars represent standard 
deviation. 
 
 
The result appeared to indicate successful stressing had been produced by 
the TNF however there remained the possibility that it was the media 
component in which the TNF was diluted that was causing stressing. As 
suggested by the manufacturer of the TNF, the initial batch had been diluted 
into RPMI media and it was not possible to extract the TNF out of this media 
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to remove all traces of media from the experiment. As a result, a subsequent 
experiment attempted to stimulate an inflammatory response simply by 
incubating cells with RPMI diluted down in HBSS to the same concentration 
as in this experiment (10 % v/v) to ascertain whether such low levels of media 
would stimulate HaCaTs in the absence of any TNF. Readings from such a 
treatment could then be compared against cells exposed to TNF. 
 
2.3.2 Comparison of media vs TNF-α as a stress mediator 
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Figure 27 – illustrates that if RPMI media is diluted to 10 % in HBSS that the same level of 
‘stress’ is produced as in cells exposed to TNF. Both sets of absorbances are almost identical 
and both are significantly higher than that of the negative control (cells exposed to WST-1 
diluted into HBSS).  Error bars represent standard deviation. 
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RPMI media diluted 1:10 in HBSS produced almost identical readings to that 
of the TNF suggesting that it was the media itself and not the TNF producing 
the apparent inflammatory response relative to the negative control. Given 
that the unstressed cells in the negative control yielded a much lower 
baseline absorbance it was now possible to establish two benchmarks for 
fully stressed and unstressed cells even though it was RPMI media and not a 
combination of TNF and FMLP that was producing the higher benchmark, as 
originally hoped. Nevertheless, it was now possible to pre-treat HaCaT cells 
with BUDAS to look for potential anti-inflammatory effects on those cells. 
 
2.3.3 Cell penetration studies 
 
 
Fig. 27 Concentration of budesonside in human airway epithelial cell lysate after either 1 or 
24 hours exposure to 0.5 µg/ml BUDAS or Pulmicort. Assayed by HPLC analysis of the cell 
lysate. Errors bars represent standard deviation, n=6 
 
The concentration of budesonide in NHBE cells after exposure to BUDAS or 
Pulmicort® at an equivalent concentration is similar after 1 hour, but greater in 
cells exposed to BUDAS after 24 hours. 
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2.3.4 Cell Retention Studies 
 
 
Fig. 28  Concentration of budesonside in human airway epithelial cell lysate after either 24 or 
48 hours incubation. In the latter treatment, cells were subjected to a media change after 24 
hours. Assayed by HPLC analysis of the cell lysate. Error bars represent standard deviation. 
N=6 
 
A greater proportion of internalized budesonide is retained in NHBE cells after 
exposure to BUDAS than with Pulmicort® at an equivalent dose (Figure 28). 
 
2.3.5 Measuring background absorbance of MTT/WST-1 in the absence 
of cells 
 
When MTT or WST-1 were diluted into HBSS the resulting levels of 
background absorbance were lower than when the reagents had been diluted 
into RPMI cell culture media (Figure 29). Furthermore, the magnitude of 
absorbance change at the end of the sampling period was also reduced when 
WST-1 dilutions were performed with HBSS. In both cases, however, 
background turnover remained at acceptably low levels. 
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Fig. 29. Changes in background absorbance of WST-1 (450 nm) and MTT (595 nm) over 
time after dilution into HBSS or RPMI 1640 cell culture medium. Error bars represent 
standard deviation (n = 3). 
 
2.3.6 Identifying the media component responsible for ROS production 
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Fig. 30. Turnover of WST-1 in HaCaT cells exposed to one of four media solutions; 1) fully 
supplemented RPMI 1640 cell culture medium diluted 10 % in HBSS, 2) unsupplemented 
RPMI 1640 cell culture medium diluted 10 % in HBSS, 3) FCS diluted to 1 % in HBSS or 4) 
HBSS. All dilutions were v/v. Error bars represent standard deviation (n=6). 
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The levels of absorbance observed in the negative control represent that of 
background turnover of WST-1 diluted in HBSS and of the three solutions 
tested 1 % FCS diluted in HBSS produced readings most similar to the 
negative control. This suggests that, at a final concentration of 1 % (v/v), FCS 
does not induce ROS production in HaCaT cells (Figure 30). 
 
In contrast, the level of absorbance observed when cells are exposed to fully 
supplemented RPMI cell culture media (diluted in HBSS) represent that of the 
positive control – fully „stressed‟ cells in which ROS production had been 
stimulated. That RPMI medium lacking serum produced a pattern of 
absorbance most similar to the positive control for the duration of the 
experiment suggests a component of the RPMI and not FCS is responsible 
for inducing the inflammatory response in HaCaT cells.  
 
2.3.7 SOD inclusion during cell stressing 
 
The inclusion of superoxide dismutase (SOD) in experimental solutions 
drastically reduced the turnover of the 10 % RPMI stress solution (a 59 % 
reduction compared to when SOD was omitted) (Figure 31). SOD inclusion 
reduced absorbance levels nearer to the baseline level of the negative control 
(HBSS –SOD) which represented the levels of absorbance in unstressed 
cells. 
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Fig. 31. Turnover of WST-1 in HaCaT cells exposed to either a ‘stress’ solution of 10 % (v/v) 
RPMI 1640 diluted into HBSS or a negative control solution of HBSS, both either in the 
presence or absence of the anti-oxidant, superoxide dismutase. Error bars represent 
standard deviation (n=6). 
 
2.3.8 Attenuation of OB after pre-treatment with corticosteroids 
 
Pre-treatment of HaCaT cells with BUDAS (which contained 5 µg/ml 
budesonide) significantly lowered the level of stressing compared to the 
positive control of fully stressed cells (Figure 32).  Unpaired student‟s t-test 
results show there to be a significant difference between BUDAS and the 
positive control (P < 0.001) but not between Pulmicort® and the positive 
control (P > 0.05) suggesting Pulmicort® failed to inhibit ROS production to 
the same extent as BUDAS. 
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Fig. 32. Pre-incubation of HaCaT cells with either a) BUDAS or b) Pulmicort
®
 over a 24 hour 
period prior to stressing. Error bars represent standard deviation (n =12). 
 
2.3.9 Stressing Cells in the presence of corticosteroids 
 
If there is no-treatment period with corticosteroids, and cells are instead 
exposed to budesonide whilst being stressed, suppression of the 
inflammatory response is immediately noted (Figure 33) with both BUDAS 
and Pulmicort®. However, with both formulations, the ability to suppress the 
inflammatory response decreases over time, to the point where, at six hours, 
there is no apparent therapeutic benefit. At time intervals of 1,2,3,4 or 5 hours 
all observed readings for BUDAS or Pulmicort are significantly lower than in 
the positive control (P < 0.001 in all cases) but at the end point of 6 hours, no 
significant difference was observed (P > 0.05). 
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Fig. 33. HaCaTs exposed to BUDAS or Pulmicort
®
 during stressing. Error bars represent 
standard deviation (n=6). 
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3. Discussion  
 
 
Cross-linked PVA nanoparticles for DNA delivery 
 
GFP detection was selected as a means of determining transfection efficiency 
as it is a widely used reporter of gene expression and provides a reliable 
indicator of transfection as the protein is only expressed upon successful 
internalization into the cell and if all subsequent barriers to gene expression 
are overcome.  
 
Results in this project confirmed the findings of Felgner et al. (1987) – that 
naked DNA is unable to produce transfection unless complexed with a carrier 
or physically delivered into the cytoplasm. 
 
Stocks of GFP plasmid were purified and tested for efficacy by transfecting 
them with a commercial transfection reagent, Lipofectin®, known to produce 
successful transfection in a variety of cell lines and even primary cells in vitro. 
Once culture conditions were optimized for Lipofectin® transfections, 
liposomal based transfection was used as a positive control technique all 
throughout the project to verify the efficacy of the plasmid stock and also the 
suitability of the culture conditions during each transfection. 
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As results confirmed the efficacy of the plasmid, experiments moved onto 
looking at hydrogel nanoparticles as DNA carriers. KP-08 nanoparticles were 
evaluated via a mobility shift assay to test whether DNA binding was 
occurring.  As in studies by Akinc et al. (2005), Chen et al. (2007) and Pack et 
al. (1999), DNA had a restricted mobility on the agarose gel when it had been 
mixed with KP-08 prior to electrophoresis. As the amount of KP-08 (in terms 
of µg) relative to DNA was increased, DNA movement across the gel 
decreased to the point where there was no movement across the gel and all 
DNA remained bound to the hydrogel (hydrogel:DNA ratio of 189:1), forming 
a distinct band visible in the well at the top of the lane. These results 
suggested that DNA was successfully forming polyplexes with KP-08 
nanoparticles. 
 
The following experiment mixed DNA with KP-08 nanoparticles with varying 
concentrations of the crosslinker, PD2000, as nanoparticle charge is 
positively related to PD2000 concentration. These results suggested a 
minimum PD2000 concentration of 0.03 % was necessary in order to bind all 
DNA in a given sample when KP-08 and DNA were mixed at a ratio around 
200:1. This experiment also demonstrated the stability of the KP-08/DNA 
polyplexes in Opti-MEM cell culture media, a pre-requisite if the polyplexes 
were to be incubated with cells during transfection studies. 
 
During transfection, NIH 3T3 cells were shown to uptake KP-08 polyplexes, 
however, the overall rate of transfection remained negligible with only 5 GFP-
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expressing cells counted on a coverslip that contained several hundred 
thousand cells. Furthermore, this result was not replicable under identical 
experiment conditions, thus questioning the validity of the result.  
 
Kimura et al. (2004) showed that the hydrophobicity of PVA nanoparticles can 
influence whether they are uptaken by cells or not, however, even when 
POVAL nanoparticles (minimal level of hydropobicity) were used in 
transfection studies during this project (identical methodologies followed to 
that described for KP-08) no GFP expression was noted. This was despite the 
fact that POVAL nanoparticles, like KP-08 nanoparticles, were shown to 
effectively bind DNA during electrophoresis studies. 
 
It was postulated that the lack of GFP expression may have been a 
consequence of inefficient endosomal escape of the polyplexes if they had 
been uptaken by cells. For that reason cells were transfected in the presence 
of chloroquine, which had been shown to increase the transfection 
efficiencies of PVA nanoparticles by Wittmar et al. (2005), incidentally, who 
also reported a lack of endosomal escape in the absence of the drug. 
However, even following clhoroquine addition, NIH 3T3 cells displayed no 
evidence of GFP expression after exposure to KP-08 or POVAL 
nanoparticles. 
 
One of the most successful polymers used in transfection research to date is 
PEI. It has been suggested that its success (again demonstrated as an 
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efficient transfector during this project) stems from the fact it is only partially 
protonated at physiological pH. Once internalizated into cells, PEI 
nanoparticles are localized in the endosome, in which the environment is 
more acidic (Wagner, 1998), and this leads to protonation as protons and 
chloride ions are pumped into the cell, providing a mechanism for endosomal 
escape due to osmotic swelling and subsequent rupture (Akinc et al. 2005). 
With this in mind we sought to examine the stability of KP-08 nanoparticles 
when placed into a more acidic environment, such as in the endosome. 
 
At pH 5.15 (similar to that of the endosome) DNA appeared to be released 
from the KP-08. However, when the experiment was repeated by making up 
fresh solutions of Opti-MEM and forming new complexes, the result was not 
reproducible. As a result it is not possible to determine from these results 
whether DNA release would occur inside or outside of the endosome in 
successfully internalized cells. 
 
There was every possibility that the lack of transfection observed during the 
project may have been because cells had simply not uptaken nanoparticles in 
the first instance, and that transfection was being prevented at the first hurdle. 
To investigate this possibility, stocks of pDNA were labelled with a 
fluorescent-rhodamine tag and examined for following transfection, as in Kaul 
& Amiji (2005). In contrast to the Lipofectin® control in which rhodamine-
labelled plasmid was conspicuous and widespread in cells following 
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transfection, cells exposed to KP-08 nanoparticles displayed little evidence of 
internalized labeled-plasmid. 
 
However, when KP-08-bound pDNA was subsequently mixed with 
Lipofectin®, to form chimeric complexes, both rhodamine-labelled plasmid and 
GFP expression was noted in cells following transfection. There remains the 
possibility that the internalized plasmid may not have been bound to KP-08 
and Lipofectin® simultaneously, and may have instead formed Lipofectin®-
DNA complexes that transfected cells as in a positive control treatment. 
However, electrophoresis results suggested that all DNA presented to the 
Lipofectin® would have been bound to the KP-08 as polyplexes were formed 
in line with previous hydrogel:DNA ratios. Although particle sizing analysis did 
not clarify the issue – with several species sized in the sample – 
electroporation was undertaken to address the same question – if polyplexes 
are delivered into cells does GFP expression take place? 
 
When HaCaT cells were electroporated with an electroporation buffer 
containing KP-08/DNA polyplexes, GFP expression was subsequently noted. 
Again, it is only assumed that the DNA had remained bound to the KP-08 at 
the point at which the cell membrane was electropermeabilised. However, as 
the total number of GFP-expressing cells counted was reduced two fold when 
cells were electroporated in the presence of the KP-08 it would appear that 
the KP-08 hindered, but did not totally prevent, subsequent gene expression 
once KP-08 nanoparticles were located inside the cell. 
 148 
 
Particle sizing analysis of the hydrogel nanoparticles revealed that they are of 
a small enough size to be endocytosed. Particle sizing measured KP-
08/pDNA polyplexes at 120 nm, whilst authors such as Kaul & Amiji (2005) 
and  Zhao et al. (2006), amongst others, have reported particle sizes in 
excess of this yet still reported successful transfection. Conductimetric 
titration results also suggest that the particles have a net positive charge and 
thus charge repulsion with the negatively charged cell membrane seems an 
unlikely explanation for the lack of cell uptake. 
 
It has been reported by Gao et al. (2007) that cell type affects transfection 
efficiency and for that reason transfection studies have been undertaken on 
four cell types – HaCaT and NIH 3T3 cell lines and primary chondrocyte and 
human airway epitelial cells – however, KP-08 has never transfected any of 
those cell types with high efficiency and even in the one instance in which 
GFP-expression was noted the result was not reproducible. In contrast, the 
Lipofectin® positive control has repeatedly produced transfection (detected by 
GFP expression) despite modification of experimental parameters such as 
target cell type, starting cell density, duration of transfection period, duration 
of time cells grown for prior to analysis etc. 
 
Collectively, the results gathered throughout the duration of the project 
suggest that the barrier to transfection with cross-linked hydrogel 
nanoparticles is inefficient cell uptake.  The nanoparticles used for 
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transfection appear of a size small enough to be endocytosed by cells and 
complex formation with pDNA appeared to be occurring.  Nevertheless, the 
target cells at present seem to lack a stimulus to uptake the formed 
polyplexes, preventing transfection from taking place. However, although they 
failed to produce transfection after exposure to cells during nebulisation, the 
fact the hydrogel nanoparticles were nebulisable and non-toxic to cells 
opened up the possibility an alternative application in the field of drug (namely 
budesonide) delivery and the same nanoparticles were used for in vitro 
investigations. 
 
Cross-linked PVA nanoparticles for drug delivery  
 
Measurement of the respiratory burst is a useful in vitro tool for studies of 
respiratory disease as it enables workers to screen possible antioxidants that 
may have potential use as anti-inflammatory agents.  
 
Previous studies have demonstrated using chemiluminescence (Braga et al. 
2005 and Dal Sasso, 2005), that budesonide can yield lower 
chemiluminescence readings in neutrophils, after exposure to fMLP or PMA. 
Budesonide was functional at concentrations of either 5 or 10 µg/ml either in 
isolation or when used in conjunction with erdosteine (Dal Sasso, 2005). 
Inclusion of the glucocorticoid receptor antagonist  mifepristone in respiratory 
burst experiments on neutrophils has inhibited the effect of budesonide on 
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luminol-amplified chemiluminescence, suggesting budesonide reacts with 
glucocorticoid receptors to exert an antioxidant activity (Braga et al., 2005). 
 
As in previous studies (Tan & Berridge, 2000) these results have 
demonstrated the use of WST-1 for measuring antioxidant activity. 
Neutrophils have been widely used for research into this area as they release 
large amounts of toxic molecules, such as reactive nitrogen and reactive 
oxygen species (Folkerts et al. 2001) that can be stimulated in vitro by 
exposing cells to fMLP (Braga et al, 2005, Dal Sasso et al. 2005, Pruett & 
Loftis, 1990) or PMA (Braga et al, 2005, Black et al, 1994, Elferink 1984, Tan 
& Berridge, 2000, Theron 1994). Here the present an alternative means of 
stimulating a SOD-inhibitable respiratory burst, using standard cell culture 
media (RPMI 1640) on the HaCaT cell line. Results suggest it is a component 
of the RPMI media itself, and not the serum supplement, that is responsible 
for producing the witnessed oxidative burst. Serum has been shown to 
increase NADPH-oxidase activity of stimulated neutrophils by preventing 
premature, oxidative inactivation of cellular energy metabolism (Theron et al. 
1994) but given that HaCaTs can circumvent this problem by consuming 
glutamine (Benavente & Jacobsen, 2008), which inadvertently leads to the 
accumulation of NADPH oxidase and subsequent ROS production, serum 
starvation did not prevent an OB from being produced in our experiments.  
 
Importantly, HPLC analysis shows our BUDAS formulation delivers more 
budesonide to NHBE cells than Pulmicort® at an equivalent concentration of 5 
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µg/ml and that a greater proportion of the delivered drug is retained in the cell. 
This is potentially a useful clinical finding as it means it may be possible to 
reduce the number of budesonide inhalations, improving patient compliance. 
 
When ROS production is stimulated in HaCaTs in the presence of 
budesonide, both BUDAS and Pulmicort demonstrate virtually identical 
readings in lowering the turnover of MTT suggesting that in the immediate 
hours of budesonide exposure the levels of active drug available in HaCaT 
cells is similar for both formulations.  Cellular uptake results indicated the 
internalization of BUDAS and Pulmicort® was similar after 1 hour, but after 24 
hours, a marked difference was observable. However, studies incorporating a 
24-hour pre-treatment period of budesonide prior to OB-stimulation reveal 
that BUDAS production at a concentration of 5 µg/ml is effective at inhibiting 
ROS production whereas Pulmicort® is not. 
 
Given the budesonide can be present in cells in both functional and esterified 
forms (Brattsand & Miller Larsson, 2003), the enhanced drug retention and 
prolonged duration of action of BUDAS over Pulmicort® that was evident in 
respiratory burst studies is most likely a consequence of increased long-term 
storage of esterified-budesonide in the cells exposed to BUDAS. When the 
intracellular concentration of budesonide decreases, budesonide esters are 
hydrolysed back into their active state (Brattsand & Miller-Larsson, 2003). 
This appears to confer the benefits of increased drug retention and a 
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prolonged duration of action with BUDAS, and may also reduce the risk of 
systemic effects in future clinical trials. 
 
These findings highlight the potential value in using cross-linked PVA-based 
Nanagel® nanoparticles to improve budesonide dissolution and delivery for 
the treatment of asthma and COPD. 
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